WO2004106381A1 - Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders - Google Patents
Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders Download PDFInfo
- Publication number
- WO2004106381A1 WO2004106381A1 PCT/EP2004/005685 EP2004005685W WO2004106381A1 WO 2004106381 A1 WO2004106381 A1 WO 2004106381A1 EP 2004005685 W EP2004005685 W EP 2004005685W WO 2004106381 A1 WO2004106381 A1 WO 2004106381A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- acid sequence
- antibody
- single chain
- bispecific single
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Definitions
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a bispecific single chain antibody construct, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD 19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions ( ⁇ _) are arranged, from N-terminus to C-terminus, in the order, VH(CD19)-V L (CD19)-VH(CD3)-VL(CD3) > VH(CD3)-V L (CD3)-VH(CD19)-VL(CD19) or VH(CD3)-VL(CD3)-VL(CD19)-V H (CD19).
- processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are disclosed.
- B-cell mediated diseases such as non- Hodgkin lymphoma
- conventional approaches to cure such diseases remain tedious and unpleasant and/or have a high risk of relapse.
- high dose chemotherapy as a primary treatment for high grade non-Hodgkin lymphoma may improve overall survival, about 50% of the patients still die of this disease (Gianni, N Engl. J. Med. 336 (1997), 1290-7; Urba, J. Natl. Cancer Inst. Monogr. (1990), 29-37; Fisher, Cancer (1994)).
- CD antigens are highly restricted to specific lineage lymphohematopoietic cells and over the past several years, antibodies directed against lymphoid-specific antigens have been used to develop treatments that were effective either in vitro or in vivo animal models (Bohlen, Blood 82 (1993), 1803-121 ; Bohlen, Cancer Res 53 (1993), 18: 4310-4; Bohlen, Cancer Res 57 (1997), 1704-9; Haagen, Clin Exp Immunol 90 (1992), 368- 75; Haagen, Cancer Immunol Immunother.
- CD19 has proved to be a very useful target.
- CD 19 is expressed in the whole B lineage from the pro B cell to the mature B cell, it is not shed, is uniformly expressed on all lymphoma cells, and is absent from stem cells (Haagen, Clin Exp Immunol 90 (1992), 368-75; Uckun, Proc. Natl. Acad. Sci. USA 85 (1988), 8603-7).
- the CD3 complex denotes an antigen that is expressed on T-cells as part of the multimolecular T-cell receptor complex. It consists of several different chains for instance ⁇ , ⁇ , ⁇ , ⁇ or/and ⁇ chains. Clustering of CD3 on T cells, e.g., by immobilized anti-CD3-antibodies, leads to T cell activation similar to the engagement of the T cell receptor but independent from its clone typical specificity. Actually, most anti-CD3-antibodies recognize the CD3 ⁇ -chain.
- the mutated OKT-3 antibodies disclosed in US 5,885,573 appear to result in comparable cell proliferations to that observed with PBMC stimulated with the original murine OKT3 and to similar amounts of cytokines produced.
- the mutated Glu-235 mAb induced smaller quantities of TNF- ⁇ and GM-CSF and no IFN- ⁇ .
- T cell proliferation was induced by Glu-235 monoclonal antibody (“mab”) using PBMC from three different donors at mab concentrations up to 10 ⁇ g/ml, suggesting that the alteration of the FcR binding region of this mab had impaired its mitogenic properties.
- T cell activation by Glu-235 mab also resulted in lower levels of expression of surface markers Leu23 and IL-2 receptor.
- US 5,929,212 discloses a recombinant antibody molecule in which the binding regions have been derived from the heavy and/or light chain variable regions of a murine anti-CD3 antibody, e.g. OKT3, and have been grafted into a human framework.
- WO 98/52975 discloses a mutated variant of the murine anti-CD3 antibody OKT3.
- the mutated OKT3 antibody is produced using a recombinant expression system and WO 98/52975 proposes that the mutated anti-CD3 antibody is more stable than the parental OKT3 protein during extended storage periods.
- US 5,955,358 discloses a method of shuffling, at the DNA level, multiple complementarity determining CamillCDR" domains, either from the same or different antibodies, meaning that their order within antibody variable domains is altered to yield new combinations of binding regions.
- OKT3 has been used as potent immunosuppressive agent in clinical transplantation to treat allograft rejection (Thistlethwaite 1984, Transplantation 38, 695-701 ; Woodle 1991, Transplantation 51 , 1207-1212; Choi 2001, Eur. J. Immunol. 31(1), 94-106).
- Major drawbacks of this therapy are T cell activation manifested in cytokine release due to cross-linking between T cells and Fc ⁇ R-bearing cells and the human anti- mouse antibody (HAMA) response.
- HAMA human anti- mouse antibody
- OKT3 or other anti-CD3-antibodies can be used as immunopotentiating agents to stimulate T cell activation and proliferation (US 6,406,696 Bluestone; US 6,143,297 Bluestone; US 6,113,901 Bluestone; Yannelly 1990, J. Immunol. Meth. 1 , 91-100).
- Anti-CD3-anti bodies have also been described as agents used in combination with anti-CD28-antibodies to induce T cell proliferation (US 6,352,694).
- OKT3 has further been used by itself or as a component of a bispecific antibody to target cytotoxic T cells to tumor cells or virus infected cells (Nitta 1990, Lancet 335, 368-376; Sanna 1995, Bio/Technology 13, 1221-1224; WO 99/54440).
- Bispecific antibodies comprising specificities for human CD19 and human CD3 which are not of the single-chain format and which retarget T-cell cytotoxicity to lymphoma cells in an MHC-independent manner have already been shown to be effective in vivo in animal models (Bohlen, Cancer Res 57 (1997), 1704-9; Demanet, Int J Cancer Suppl 7 (1992), 67-8) as well as in some pilot clinical trials. So far these antibodies were constructed by hybrid-hybridoma techniques, by covalently linking the monoclonal antibodies (Anderson, Blood 80 (1992), 2826-34) or by a diabody approach (Kipriyanov, Int. J. Cancer 77 (1998), 763-772).
- constructs which can be produced in large amounts by reasonably high levels of expression of the recombinant constructs and by adequate purification methods after expression.
- extremely low amounts of pure protein are obtained, it becomes prohibitively cumbersome and/or costly to generate therapeutically relevant amounts of such constructs.
- proteinaceous medicaments intended for parental administration these medicaments should be highly active and potent, even in low concentrations, in order to avoid adverse side-effects due to excessive protein concentrations or voluminous infusion/injection solutions.
- Disadvantages of highly-dosed proteinaceous medicaments or highly-dosed medicaments based on nucleic acids comprise, inter alia, the promotion of hypersensitivities and inflammatory events, in particular at the site of administration.
- the technical problem of the present invention is the provision of means and methods for the generation of well tolerated and convenient medicaments for the treatment and or amelioration of B-cell related or B-cell mediated disorders.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a bispecific single chain antibody construct, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) are arranged, from N-terminus to C- terminus, in the order,
- VL and VH means the variable domain of the light and heavy chain of specific anti-CD19 (CD19) and anti-CD3 (CD3) antibodies.
- the term "pharmaceutical composition” relates to a composition for administration to a patient, preferably a human patient.
- the pharmaceutical composition comprises a composition for parenteral, transdermal, intraluminal, intraarterial, intrathecal administration or by direct injection into tissue. It is in particular envisaged that said pharmaceutical composition is administered to a patient via infusion or injection. Administration of the suitable compositions may be effected by different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration.
- the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier.
- Suitable pharmaceutical carriers include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions, etc.
- Compositions comprising such carriers can be formulated by well known conventional methods. These pharmaceutical compositions can be administered to the subject at a suitable dose. The dosage regiment will be determined by the attending physician and clinical factors. As is well known in the medical arts, dosages for any one patient depend upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently.
- a preferred dosage for administration might be in the range of 0.24 ⁇ g to 48 mg, preferably 0.24 ⁇ g to 24 mg, more preferably 0.24 ⁇ g to 2.4 mg, even more preferably 0.24 ⁇ g to 1.2 mg and most preferably 0.24 ⁇ g to 240 ⁇ g units per kilogram of body weight per day. Particularly preferred dosages are recited herein below. Progress can be monitored by periodic assessment. Dosages will vary but a preferred dosage for intravenous administration of DNA is from approximately 10 6 to 10 12 copies of the nucleic acid molecule, preferably a DNA molecule.
- the pharmaceutical compositions of the invention comprising proteinaceous or nucleic acid compounds described herein may be administered locally or systematically.
- Administration will generally be parenterally, e.g., intravenously; DNA may also be administered directed to the target site, e.g., by biolistic delivery to an internal or external target site or by catheter to a site in an artery.
- Preparations for parenteral administration include sterile aqueous or non- aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, inert gases and the like.
- the pharmaceutical composition of the present invention might comprise proteinaceous carriers, like, e.g., serum albumin or immunoglobulin, preferably of human origin.
- the pharmaceutical composition of the invention might comprise, in addition to the proteinaceous bispecific single chain antibody constructs or nucleic acid molecules or vectors encoding the same (as described in this invention), further biologically active agents, depending on the intended use of the pharmaceutical composition.
- agents might be drugs acting on the gastro-intestinal system, drugs acting as cytostatica, drugs preventing hyperurikemia, drugs inhibiting immunoreactions (e.g. corticosteroids), drugs acting on the circulatory system and/or agents such as T-cell co-stimulatory molecules or cytokines known in the art.
- bispecific single chain antibody construct relates to a construct comprising one domain consisting of variable regions (or parts thereof) as defined above, capable of specifically interacting with/binding to human CD3 and comprising a second domain consisting of variable regions (or parts thereof) as defined above, capable of specifically interacting with/binding to human CD 19. Said binding/interaction is also understood to define a "specific recognition”.
- specifically recognizing means in accordance with this invention that the antibody molecule is capable of specifically interacting with and/or binding to at least two amino acids of each of the human target molecule as defined herein. Said term relates to the specificity of the antibody molecule, i.e. to its ability to discriminate between the specific regions of the human target molecule as defined herein.
- the specific interaction of the antigen-interaction-site with its specific antigen may result in an initiation of a signal, e.g. due to the induction of a change of the conformation of the antigen, an oligomerization of the antigen, etc. Further, said binding may be exemplified by the specificity of a "key-lock-principle".
- specific motifs in the amino acid sequence of the antigen-interaction-site and the antigen bind to each other as a result of their primary, secondary or tertiary structure as well as the result of secondary modifications of said structure.
- the specific interaction of the antigen- interaction-site with its specific antigen may result as well in a simple binding of said site to the antigen.
- the term "specific interaction" as used in accordance with the present invention means that the bispecific single chain construct does not or essentially does not cross-react with (poly) peptides of similar structures.
- Cross-reactivity of a panel of bispecific single chain construct under investigation may be tested, for example, by assessing binding of said panel of bispecific single chain construct under conventional conditions (see, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1988 and Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1999) to the (poly)peptide of interest as well as to a number of more or less (structurally and/or functionally) closely related (poly)peptides.
- an antigen-interaction-site to antigens like antigens of the selectin family, integrins and of the family of growth factors like EGF.
- An other example for said interaction which is also particularly comprised by said definition, is the interaction of an antigenic determinant (epitope) with the antigenic binding site of an antibody.
- binding to/interacting with may also relate to a conformational epitope, a structural epitope or a discountinuous epitope consisting of two regions of the human target molecules or parts thereof.
- a conformational epitope is defined by two or more discrete amino acid sequences separated in the primary sequence which come together on the surface of the molecule when the polypeptide folds to the native protein (Sela, (1969) Science 166, 1365 and Laver, (1990) Cell 61, 553-6).
- discontinuous epitope means in context of the invention non-linear epitopes that are assembled from residues from distant portions of the polypeptide chain. These residues come together on the surface of the molecule when the polypeptide chain folds into a three-dimensional structure to constitute a conformational/structural epitope.
- the "specific binding" of an antibody is characterized primarily by two parameters: a qualitative parameter (the binding epitope, or where the antibody binds) and a quantitative parameter (the binding affinity, or how strongly it binds where it does).
- Which epitope is bound by an antibody can advantageously be determined by e.g. known FACS methodology, peptide-spot epitope mapping, mass spectroscopy.
- the strength of antibody binding to a particular epitope may be advantageously be determined by e.g. known BIAcore and/or ELISA methodologies. A combination of such techniques allows the calculation of a signahnoise ratio as a representative measure of binding specificity.
- the signal represents the strength of antibody binding to the epitope of interest
- the noise represents the strength of antibody binding to other, non-related epitopes differing from the epitope of interest.
- any time an antibody binds more frequently and/or strongly to one epitope than another epitope such antibody may be said to bind the former epitope specifically.
- a signahnoise ratio for an epitope of interest which is about 50-fold higher than for other epitopes different from the epitope of interest may be taken as an indication that the antibody evaluated binds the epitope of interest in a specific manner, i.e. is a "specific binder".
- a part of a variable region may be at least one CDR ("Complementary determining region"), most preferably at least the CDR3 region.
- Said two domains/regions in the single chain antibody construct are preferably covalently connected to one another as a single chain. This connection can be effected either directly (domain 1 directed against CD3 - domain2 directed against CD 19 or domain 1 directed against CD 19 - domain2 directed against CD3) or through an additional polypeptide linker sequence (domain 1 - linker sequence - domain2).
- this linker is preferably of a length and sequence sufficient to ensure that each of the first and second domains can, independently from one another, retain their differential binding specificities.
- the "bispecific single chain antibody construct" to be employed in the pharmaceutical composition of the invention is a bispecific single chain Fv (scFv).
- Bispecific single chain molecules are known in the art and are described in WO 99/54440, Mack, J. Immunol. (1997), 158, 3965-3970, Mack, PNAS, (1995), 92, 7021-7025, Kufer, Cancer Immunol. Immunother., (1997), 45, 193-197, L ⁇ ffler, Blood, (2000), 95, 6, 2098-2103, Br ⁇ hl, Immunol., (2001), 166, 2420-2426, Kipriyanov, J. Mol. Biol., (1999), 293, 41-56.
- single-chain as used in accordance with the present invention means that said first and second domain of the bispecific single chain construct are covalently linked, preferably in the form of a co-linear amino acid sequence encodable by a single nucleic acid molecule.
- CD19 denotes an antigen that is expressed in the B lineage such as in the pro B cell and the mature B cell, it is not shed, is uniformly expressed on all lymphoma cells, and is absent from stem cells (Haagen (1992) loc.cit; Uckun (1988) PNAS 85, 8603-8607).
- CD3 denotes an antigen that is expressed on T-cells as part of the multimolecular T-cell receptor complex and that consists of at least three different chains CD3 ⁇ , CD3 ⁇ and CD3 ⁇ .
- Clustering of CD3 on T-cells e.g., by immobilized anti-CD3-antibodies, leads to T-cell activation similar to the engagement of the T-cell receptor but independent from its clone typical specificity. Actually, most anti-CD3-antibodies recognize the CD3 ⁇ -chain.
- Antibodies that specifically recognize CD19 or CD3 antigen are described in the prior art, e.g., in Dubel (1994), J. Immunol. Methods 175, 89-95; Traunecker (1991) EMBO J. 10, 3655-3699 or Kipriyanov, (1998), loc.cit. Further illustrative examples are listed below. Furthermore, antibodies directed against human CD3 and/or human CD 19 can be generated by conventional methods known in the art.
- variable regions (corresponds to VH),VL (corresponds to VL)) or parts thereof (e.g. CDRs) in the format VH(CD19)- VL(CD19)-VH(CD3)-V L (CD3), V H (CD3)-V L (CD3)-VH(CD19)-VL(CD19) or V H (CD3)- VL(CD3)-VL(CD19)-VH(CD19)
- these constructs are advantageous over constructs of similar formats, like V L (CD3)-VH(CD3)-VL(CD19)-VH(CD19), VL(CD3)-VH(CD3)-VH(CD19)-VL(CD19) ) V L (CD19)-VH(CD19)-VL(CD3) or VH(CD19)-V L (CD19)-V
- the latter four constructs/construct formats are characterized by less advantageous cytotoxic activity as reflected by EC 50 values and/or less efficient or complete purifications as shown in the appended examples. It was in particular surprising that the anti-CD3 part of the single chain constructs to be employed in accordance with the invention are highly bioactive in N- as well as C-terminal position, whereas arrangements in VH(CD3)-VL(CD3) are particularly preferred.
- the constructs to be employed in the pharmaceutical composition of the invention are characterized by advantageous production and purification properties as well as by their high bioactivity, i.e. their desired cytotoxic activity. The corresponding high bioactivity is reflected by low to very low EC 5 o values as determined in cytotoxicity tests.
- EC50 corresponds, in context of this invention, to EC 5 o values as determined according to the methods known in the art and as illustrated in the appended examples: a standard dose-response curve is defined by four parameters: the baseline response (Bottom), the maximum response (Top), the slope of dose- response increase, and the drug concentration that elicits a response halfway between baseline and maximum (EC50). EC50 is defined as the concentration of a drug or molecule that elicits a response half way between the baseline (Bottom) and maximum response (Top). The percentage of cell lysis (i.e.
- cytotoxic activity may be determined by, inter alia, release assays disclosed herein above, for example, 51 Cr release assays, LDH-release assays, calcein release assays and the like. Most preferably, in the context of this invention fluorochrome release assays are employed as illustrated in the appended examples.
- strong cytotoxic activity against CD19-positive cells relates to a molecule comprising EC 50 values ⁇ /- (less or equal to) 500 pg/ml, more preferably ⁇ /-400 pg/ml, even more preferably ⁇ /- 300 pg/ml, even more preferably ⁇ /-250 pg/ml, most preferably ⁇ /-200 pg/ml.
- the VH and VL regions of said CD3 specific domain are derived from a CD3 specific antibody selected from the group consisting of X35-3, VIT3, BMA030 (BW264/56), CLB-T3/3, CRIS7, YTH12.5, F111-409, CLB-T3.4.2, WT31, WT32, SPv-T3b, 11D8, XIII-141 , XIII-46, XIII-87, 12F6, T3/RW2-8C8, T3/RW2-4B6, OKT3D, M-T301, SMC2 and F101.01.
- a CD3 specific antibody selected from the group consisting of X35-3, VIT3, BMA030 (BW264/56), CLB-T3/3, CRIS7, YTH12.5, F111-409, CLB-T3.4.2, WT31, WT32, SPv-T3b, 11D8, XIII-141 , XIII-46, XIII-87, 12F6, T3/RW
- CD3-specific antibodies are well known in the art and, inter alia, described in Tunnacliffe (1989), Int. Immunol. 1 , 546-550.
- said VH and VL regions of said CD3 specific domain are derived from OKT-3 (as defined and described above) or TR-66.
- said VH and VL regions are or are derived from an antibody/antibody derivative specifically directed against CD3 described by Traunecker (1991), EMBO J. 10, 3655-3659.
- said VH and VL regions are derived from antibodies/antibody derivatives and the like which are capable of specifically recognizing human CD3 epsilon in the context of other TCR subunits, e.g. in mouse T cells transgenic for human CD3 epsilon. These transgenic mouse cells express human CD3 epsilon in a native or near native conformation. Accordingly, the VH and VL regions derived from a CD3-epsilon- specific antibody are most preferred in accordance with this invention and said (parental) antibodies should be capable of specifically binding epitopes reflecting the native or near native structure or a conformational epitope of human CD3 presented in context of the TCR complex.
- TCR context is required for recognition of CD3 epsilon.
- CD3 gamma and/or delta being associated with epsilon, are also involved in binding of "group II” antibodies. All three subunits express immuno- tyrosine activation motifs (ITAMs) which can be tyrosine phosphorylated by protein tyrosine kinases.
- ITAMs immuno- tyrosine activation motifs
- the VH (CD3) ⁇ L (CD3)- regions (or parts thereof) to be employed in the bispecific single chain constructs comprised in the inventive pharmaceutical composition are preferably derived from antibodies directed against human CD3 and classified as "group II" by Tunnacliffe (1989), loc.cit..
- Antibodies/antibody molecules/antibody derivatives directed against human CD19 which provide for variable regions (VH and VL) to be employed in the bispecific single chain construct(s) comprised in the inventive pharmaceutical composition are also well known in the art and illustrated in the appended examples.
- Preferred antibodies directed to human CD 19 are: 4G7 (Meecker (1984) Hybridoma 3, 305-20); B4 (Freedman (1987) Blood 70, 418-27; B43 (Bejcek (1995) Cancer Res. 55, 2346-51); BU12 (Flavell (1995) Br. J. Cancer 72, 1373-9); CLB-CD19 (De Rie (1989) Cell. Immunol. 118, 368-81); Leu-12 (MacKenzie (1987), J. Immunol. 139, 24-8); SJ25-C1 (GenTrak, Plymouth Meeting, Pa)
- VH(CD19) and VL(CD19) regions are derived from the antibody provided by the HD37 hybridoma (Pezzutto (1997), J. Immunol. 138, 2793-9).
- Fv the minimum antibody fragment which contains a complete antigen recognition and binding site, consists of a dimer of one heavy and one light chain variable domain (VH and VL) in non-covalent association.
- VH and VL variable domains
- the three CDRs of each variable domain interact to define an antigen binding site on the surface of the VH-VL dimer.
- the six CDRs confer antigen binding specificity to the antibody.
- Frameworks (FRs) flanking the CDRs have a tertiary structure which is essentially conserved in native immunoglobulins of species as diverse as human and mouse. These FRs serve to hold the CDRs in their appropriate orientation.
- the constant domains are not required for binding function, but may aid in stabilizing VH-VL interaction.
- the bispecific antibody constructs provided in the pharmaceutical composition of the invention are further modified.
- the bispecific single chain antibody construct in the format V H (CD19)-VL(CD19)-V H (CD3)-VL(CD3), V H (CD3)-V L (CD3)- VH(CD19)-V L (CD19) or VH(CD3)-V L (CD3)-VL(CD19)-V H (CD19) as defined herein are deimmunized.
- at least the CD3-binding portion is deimmunized. Deimmunization entails carrying out substitutions of amino acids within potential T cell epitopes.
- the pharmaceutical composition of the invention comprises a bispecific single chain antibody construct in the format VH(CD19)- VL(CD19)-V H (CD3)-VL(CD3), V H (CD3)-V L (CD3)-V H (CD19)-VL(CD19) or V H (CD3)- VL(CD3)-VL(CD19)-VH(CD19) as defined above, wherein said VH region comprises at least one CDR3 region (CDR-H3 or CDR-3 of VH) comprising the amino acid sequence: SEQ ID NO. 54 or 77.
- CDR-region denotes the "complementary determining region " of an antibody molecule. Accordingly, the term “CDR-3 region”, synonymous with the term “CDR3 region”, relates to the "complementary determining region 3" of an antibody molecule/antibody construct. The same applies, mutatis mutandis, for corresponding CDR-2 and CDR-1 regions. It is envisaged and preferred that the bispecific single chain construct comprised in the pharmaceutical composition of the present invention does not only comprise CDR-3 regions, but also comprises CDR-1 or CDR-2 region(s) of variable regions/variable domains (VH/VL) of antibodies/antibody molecules directed against human CD3 and human CD19.
- VH/VL variable regions/variable domains
- the said molecule comprises at least one CDR-3 region of a VH and at least one CDR-3 region of an VL-domain of an antibody directed against CD3 as well as at least one CDR-3 region of an VH and at least one CDR-3 region of a VL- domain of an antibody directed against CD 19.
- the bispecific single chain construct of the inventive pharmaceutical composition comprises in addition at least one further CDR-1 region and/or at least one further CDR-2 region in the VH and VL domains defined herein.
- the bispecific single chain construct defined herein may comprise CDR-1, CDR-2, CDR-3 region of VL as well as CDR-1 , CDR-2, CDR-3 region of VH of an antibody/antibody molecule directed against human CD3, preferably human CD3 epsilon, and comprises, in addition, CDR-1 , CDR-2, CDR-3 region of VL as well as CDR-1 , CDR-2, CDR-3 region of VH of an antibody/antibody molecule directed against human CD19.
- said VH (CD3) region comprises at least one CDR2 region comprising the amino acid sequence: SEQ ID NO. 53 or 76. It is also envisaged that said VH (CD3) region comprises at least one CDR1 region comprising the amino acid sequence: SEQ ID NO. 52 or 75.
- the VL (CD3) region comprises, preferably, at least one CDR3 region comprising the amino acid sequence: SEQ ID NO. 57 or 74.
- the VL (CD3) may comprise at least one CDR2 region comprising the amino acid sequence: SEQ ID NO. 56 or 73.
- the VL (CD3) may also comprise at least one CDR1 region comprising the amino acid sequence: SEQ ID NO. 55 or 72.
- the constructs comprised in the inventive pharmaceutical composition comprise at least one CDR-3 of a VH-region of an antibody directed against human CD3, at least one CDR-3 of a VL-region of an antibody directed against human CD3, at least one CDR-3 of a VH-region of an antibody directed against human CD19 and at least one CDR-3 of a VL-region of an antibody directed against human CD19.
- the bispecific single chain constructs comprised in the inventive pharmaceutical composition comprise VH and VL regions which comprise not only CDR-3 but also CDR1 and/or CDR2 regions.
- CDR-regions preferably CDR1 regions, more preferably CDR1 regions and CDR2 regions, most preferably CDR1 regions, CDR2 regions and CDR3 regions as defined herein may be employed to generate further bispecific single chain constructs defined herein.
- the bispecific single chain constructs comprised in the inventive pharmaceutical composition are derived from the parental antibodies as disclosed herein and share, as disclosed above, the CDR-3 domain of the VH-region and the CDR-3 domain of the VL-region with said parental antibodies.
- the bispecific single chain constructs comprised in the inventive pharmaceutical composition also comprises modified CDR regions. It is, e.g. envisaged that in particular CDR2 and/or CDR1 regions (or frameworks or linkers between CDRs) are deimmunized.
- the bispecific single chain antibody construct comprised in the inventive pharmaceutical composition comprises an amino acid sequence selected from the group consisting of (a) an amino acid sequence as depicted in SEQ ID NOs 2, 10 or 14; (b) an amino acid sequence encoded by a nucleic acid sequence as shown in SEQ ID NOs 1 , 9 or 13; (c) an amino acid sequence encoded by a nucleic acid sequence hybridizing under stringent conditions to the complementary nucleic acid sequence of (b); and (d) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence of (b).
- hybridizing refers to polynucleotides/nucleic acid sequences which are capable of hybridizing to the polynucleotides encoding bispecific single chain constructs as defined herein or parts thereof. Therefore, said polynucleotides may be useful as probes in Northern or Southern Blot analysis of RNA or DNA preparations, respectively, or can be used as oligonucleotide primers in PCR analysis dependent on their respective size.
- said hybridizing polynucleotides comprise at least 10, more preferably at least 15 nucleotides in length while a hybridizing polynucleotide of the present invention to be used as a probe preferably comprises at least 100, more preferably at least 200, or most preferably at least 500 nucleotides in length.
- hybridization conditions are referred to in standard text books such as Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (2001) N.Y.
- Preferred in accordance with the present inventions are polynucleotides which are capable of hybridizing to the polynucleotides of the invention or parts thereof, under stringent hybridization conditions.
- “Stringent hybridization conditions” refer, i.e. to an overnight incubation at 42°C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 ⁇ g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1 x SSC at about 65°C. Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the invention at lower stringency hybridization conditions.
- Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature.
- washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).
- blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations.
- the inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.
- variable domains comprised in the herein described bispecific single chain constructs are connected by additional linker sequences.
- peptide linker defines in accordance with the present invention an amino acid sequence by which the amino acid sequences of the first domain and the second domain of the monomer of the trimeric polypeptide construct of the invention are linked with each other.
- An essential technical feature of such peptide linker is that said peptide linker does not comprise any polymerization activity.
- a particularly preferred peptide linker is characterized by the amino acid sequence Gly-Gly-Gly- Gly-Ser, i.e. Gly Ser, or polymers thereof, i.e. (Gly 4 Ser)x, where x is an integer 1 or greater.
- peptide linker which comprise the absence of the promotion of secondary structures are known in the art and described e.g. in Dall'Acqua et al. (Biochem. (1998) 37, 9266-9273), Cheadle et al. (Mol Immunol (1992) 29, 21-30) and Raag and Whitlow (FASEB (1995) 9(1), 73-80).
- peptide linkers which comprise fewer amino acid residues.
- An envisaged peptide linker with less than 5 amino acids comprises 4, 3, 2 or one amino acid(s) wherein Gly-rich linkers are preferred.
- a particularly preferred "single" amino acid in context of said "peptide linker” is Gly.
- said peptide linker may consist of the single amino acid Gly.
- peptide linkers which also do not promote any secondary structures are preferred.
- the linkage of said domains to each other can be provided by, e.g. genetic engineering, as described in the examples. Methods for preparing fused and operatively linked bispecific single chain constructs and expressing them in mammalian cells or bacteria are well-known in the art (e.g. WO 99/54440 or Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001).
- the present invention also provides for a pharmaceutical composition
- a pharmaceutical composition comprising a nucleic acid sequence encoding a bispecific single chain antibody construct as defined above, i.e. a bispecific construct in the format VH(CD19)-VL(CD19)- VH(CD3)-VL(CD3), VH(CD3)-VL(CD3)-VH(CD19)-VL(CD19) or VH(CD3)-VL(CD3)- VL(CD19)-VH(CD19).
- nucleic acid sequences encoding bispecific constructs of the formats VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3) and VH(CD3)- VL(CD3)-VH(CD19)-VL(CD19) are each especially advantageous for inclusion in such pharmaceutical compositions.
- a nucleic acid sequence encoding a bispecific construct of, for example, the format VH(CD19)-VL(CD19)-VL(CD3)- VH(CD3) is very poorly suited for inclusion in pharmaceutical compositions, the latter being very poorly producible/isolatable.
- Said nucleic acid molecule may be a naturally occurring nucleic acid molecule as well as a recombinant nucleic acid molecule.
- the nucleic acid molecule of the invention may, therefore, be of natural origin, synthetic or semi-synthetic. It may comprise DNA, RNA as well as PNA and it may be a hybrid thereof.
- regulatory sequences may be added to the nucleic acid molecule of the invention.
- promoters, transcriptional enhancers and/or sequences which allow for induced expression of the polynucleotide of the invention may be employed.
- a suitable inducible system is for example tetracycline-regulated gene expression as described, e.g., by Gossen and Bujard (Proc. Natl. Acad. Sci. USA 89 (1992), 5547-5551) and Gossen et al. (Trends Biotech. 12 (1994), 58-62), or a dexamethasone-inducible gene expression system as described, e.g. by Crook (1989) EMBO J. 8, 513-519 .
- nucleic acid molecules may contain, for example, thioester bonds and/or nucleotide analogues. Said modifications may be useful for the stabilization of the nucleic acid molecule against endo- and/or exonucleases in the cell. Said nucleic acid molecules may be transcribed by an appropriate vector containing a chimeric gene which allows for the transcription of said nucleic acid molecule in the cell.
- polynucleotide of the invention can be used for "gene targeting" or "gene therapeutic” approaches.
- said nucleic acid molecules are labeled.
- nucleic acid molecule(s) may be a recombinantly produced chimeric nucleic acid molecule comprising any of the aforementioned nucleic acid molecules either alone or in combination.
- the nucleic acid molecule is part of a vector.
- the present invention therefore also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a vector comprising the nucleic acid molecule described in the present invention.
- the vector of the present invention may be, e.g., a plasmid, cosmid, virus, bacteriophage or another vector used e.g. conventionally in genetic engineering, and may comprise further genes such as marker genes which allow for the selection of said vector in a suitable host cell and under suitable conditions.
- the vector to be employed in the generation of the bispecific single chain constructs described herein or to be employed in a pharmaceutical composition of the present invention may, in addition to the nucleic acid sequences of the invention, comprise expression control elements, allowing proper expression of the coding regions in suitable hosts.
- expression control elements are known to the artisan and may include a promoter, a splice cassette, translation initiation codon, translation and insertion site for introducing an insert into the vector.
- said nucleic acid molecule is operatively linked to said expression control sequences allowing expression in eukaryotic or prokaryotic cells.
- Control elements ensuring expression in eukaryotic and prokaryotic cells are well known to those skilled in the art. As mentioned herein above, they usually comprise regulatory sequences ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilization of the transcript. Additional regulatory elements may include transcriptional as well as translational enhancers, and/or naturally-associated or heterologous promoter regions.
- Possible regulatory elements permitting expression in for example mammalian host cells comprise the CMV- HSV thymidine kinase promoter, SV40, RSV-promoter (Rous Sarcoma Virus), human elongation factor 1 ⁇ -promoter, the glucocorticoid-inducible MMTV-promoter (Moloney Mouse Tumor Virus), metallothionein- or tetracyclin-inducible promoters, or enhancers, like CMV enhancer or SV40-enhancer.
- specific promoters can be employed. Said promoters are known in the art and, inter alia, described or mentioned in Hendon (2002), Clin. Immunol.
- regulatory elements may also comprise transcription termination signals, such as SV40-poly-A site or the tk-poly-A site, downstream of the polynucleotide.
- suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pRc/CMV, pcDNAI, pcDNA3 (In-vitrogene), pSPORTI (GIBCO BRL), pX (Pagano (1992) Science 255, 1144-1147), yeast two-hybrid vectors, such as pEG202 and dpJG4-5 (Gyuris (1995) Cell 75, 791-803), or prokaryotic expression vectors, such as lambda gt11 or pGEX (Amersham-Pharmacia).
- the vector may further comprise nucleic acid sequences encoding for secretion signals.
- nucleic acid sequences are well known to the person skilled in the art.
- leader sequences capable of directing the peptides of the invention to a cellular compartment may be added to the coding sequence of the nucleic acid molecules of the invention and are well known in the art.
- the leader sequence(s) is (are) assembled in appropriate phase with translation, initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein, or a protein thereof, into the periplasmic space or extracellular medium.
- the heterologous sequence can encode a fusion protein including an C- or N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.
- the vector Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and, as desired, the collection and purification of the bispecific single chain constructs described herein may follow.
- the invention also relates, accordingly, to hosts/host cells which comprise a vector as defined herein. Such hosts may be useful for in processes for obtaining bispecifc single chain constructs comprised in the pharmaceutical composition of the invention as well as directly in medical/pharmaceutical settings. Said host cells may also comprise transduced or transfected white blood cells, such as lymphocyte cells, preferably adult cells. Such host cells may be useful in transplantation therapies.
- the vector as well as the nucleic acid molecule described herein may be employed in gene therapy approaches.
- Gene therapy which is based on introducing therapeutic genes into cells by ex-vivo or in-vivo techniques is one of the most important applications of gene transfer.
- Suitable vectors, methods or gene- delivering systems for in-vitro or in-vivo gene therapy are described in the literature and are known to the person skilled in the art; see, e.g., Giordano, Nature Medicine 2 (1996), 534-539; Schaper, Circ. Res. 79 (1996), 911-919; Anderson, Science 256 (1992), 808-813; Isner, Lancet 348 (1996), 370-374; Muhlhauser, Circ. Res.
- said vectors and/or gene delivery systems are also described in gene therapy approaches in blood, lymphocytes, bone marrow and corresponding stem cells; see, e.g. Hendon (2002), Clin. Immunol. 103, 145-153; Chinnosamy (2000) Blood 96, 1309-1316; Zhang (2003) J. Acq. Immun. Def. Synd. 245-254; Kaiser (2003) Science 299, 495; Hacein-Bay (2002) Int. J. Hemat. 76, 295-298; Hacein-Bay (2002) New Eng. J. Med. 346, 1185-1193; Ainti (2002) Science 296, 2410-2413.
- the nucleiG acid molecules and vectors comprised in the pharmaceutical composition of the invention may be designed for direct introduction or for introduction via liposomes, viral vectors (e.g. adenoviral, retroviral), electroporation, ballistic (e.g. gene gun) or other delivery systems into the cell.
- viral vectors e.g. adenoviral, retroviral
- electroporation e.g. ballistic
- ballistic e.g. gene gun
- baculoviral system can be used as a eukaryotic expression system in insect cells for the nucleic acid molecules of the invention.
- the introduction and gene therapeutic approach should, preferably, lead to the expression of a functional bispecific single chain construct as defined herein, whereby said expressed antibody molecule is particularly useful in the treatment, amelioration and/or prevention of B- cell related malignancies as defined herein.
- the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming of transfecting eukaryotic host cells, but control sequences for prokaryotic hosts may also be used.
- the vector Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and as desired, the collection and purification of the bispecific single chain constructs may follow; see, e.g., the appended examples.
- a pharmaceutical composition comprising a vector encoding a bispecific single chain construct in the format VH(CD19)-V L (CD19)-VH(CD3)-VL(CD3),
- V H CD3-V L (CD3)-VH(CD19)-VL(CD19) or
- the pharmaceutical composition of the invention may also comprise a proteinaceous compound capable of providing an additional activation signal for immune effector cells.
- a proteinaceous compound capable of providing an additional activation signal for immune effector cells.
- Such compounds may comprise, but are not limited to CD28 engagers, ICOS engagers, 41 BB engagers, OX40 engagers, CD27 engagers, CD30 engagers, NKG2D engagers, IL2-R engagers or IL12-R engagers.
- said "proteinaceous compounds” providing an activation signal for immune effector cells” may be, e.g. a further primary activation signal, or costimulatory (second) signal or any other accessory (third) activation signal. Examples are a TCR or TCR-Iike signal.
- Preferred formats of proteinaceous compounds comprise additional bispecific antibodies and fragments or derivatives thereof, e.g. bispecific scFv.
- Proteinaceous compounds can comprise, but are not limited to, scFv fragments specific for 4-1 BB, OX 40, CD27, CD70 or the receptors for B7-RP1, B7-H3 as well as scFv fragments specific for the T cell receptor or superantigens.
- Superantigens directly bind to certain subfamilies of T cell receptor variable regions in an MHC- independent manner thus mediating the primary T cell activation signal.
- the proteinaceous compound may also provide an activation signal for an immune effector cell which is a non-T cell.
- Examples for immune effector cells which are non- T cells comprise, inter alia, NK cells.
- a process for the production of a pharmaceutical composition of the invention comprises culturing a host defined above under conditions allowing the expression of the bispecific single chain antibody construct as defined herein and recovering the produced bispecific single chain antibody construct from the culture. The corresponding process is illustrated in the appended examples.
- the invention relates to the use of a bispecific single chain antibody construct, a nucleic acid sequence, a vector and/or a host as defined herein for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of a proliferative disease, a mimimal residual cancer, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, a viral disease, allergic reactions, parasitic reactions, graft-versus-host diseases host-versus-graft diseases or B-cell malignancies, wherein said pharmaceutical composition optionally further comprises a proteinaceous compound capable of providing an activation signal for immune effector cells.
- a method for the prevention, treatment or amelioration of a proliferative disease, a mimimal residual cancer, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, viral disease, allergic reactions, parasitic reactions, graft-versus-host diseases, host- versus-graft diseases, or B-cell malignancies comprises the step of administering to a subject in need of such a prevention, treatment or amelioration a pharmaceutical composition of the invention.
- said subject is preferably said subject is a human.
- the tumorous disease to be treated with the pharmaceutical composition of the invention may be a minimal residual cancer, for example, a minimal residual lymphoma or leukemia.
- the autoimmune disease to be treated with the pharmaceutical composition of the invention may be in inflammatory autoimmune disease, for example, rheumatoid arthritis.
- a bispecific single chain antibody construct, a nucleic acid sequence, a vector and/or a host as described herein is/are used for the preparation of a pharmaceutical composition for depletion 5 of B-cells.
- the B cell malignancy to be treated with the pharmaceutical composition of the invention is in a most preferred embodiment non-Hodgkin lymphoma, B-cell leukemias or Hodgkin lymphoma. Accordingly, the present invention provides for a
- method for the treatment of B-cell malignancies, B-cell mediated autoimmune diseases or the depletion of B-cells and/or for a method delaying a pathological condition which is caused by B-cell disorders comprising administering the pharmaceutical composition of the invention into a mammal, preferably a human, affected by said malignancies, disease and/or pathological condition.
- kits comprising a bispecific single chain antibody construct, a nucleic acid sequence, a vector and/or a host as defined above.
- Said kit is particularly useful in the preparation of the pharmaceutical composition of the present invention and may, inter alia, consist of a container useful for injections or
- the kit of the present invention further comprises, optionally (a) buffer(s), storage solutions and/or remaining reagents or materials required for the conduct of medical or scientific purposes.
- parts of the kit of the invention can be packaged individually in vials or bottles or in combination in containers or multicontainer units.
- the kit of the present invention may be
- kits 5 advantageously used, inter alia, for carrying out the method of the invention and could be employed in a variety of applications referred herein, e.g., as research tools or medical tools.
- the manufacture of the kits preferably follows standard procedures which are known to the person skilled in the art.
- Figure 1A Schematic composition of VL/VH domain arrangements in anti-CD19 / anti-CD3 single chain bispecific antibodies showing the binding sites of PCR primers.
- A1, A2, B1 and B2 denote the positions, from the N-terminus to the C-terminus of the various V-regions used in constructing the anti-CD 19 / anti-CD3 single chain bispecific antibodies.
- A1, A2, B1 and B2 denote the positions, from the N- terminus to the C-terminus of the various V-regions used in constructing the anti- CD19 / anti-CD3 single chain bispecific antibodies.
- FIG. 2 Bispecific single chain antibody elution pattern from a Zn-chelating Fractogel® column (IMAC) at 280 nm.
- the bottom line showing a first, minor step at 600 ml retention time and a second, major step at 700 ml indicates the theoretical gradient of elution buffer containing 0.5 M imidazole.
- High adsorption at 280 nm from 100-500 ml retention time was due to non-bound protein in the column flow through. Protein from the elution peak at 670.05 ml retention time was used for further purification.
- FIG 3 Bispecific single chain antibody elution pattern from a Sephadex S200 gel filtration column at 280 nm.
- the protein peak at 81.04 ml retention time containing bispecific antibodies against CD3 and CD 19 corresponds to a molecular weight of 52 kD. Fractions were collected from 50-110 ml retention time and were indicated with black arrows numbered from 5-35.
- Figure 4 Representative SDS-PAGE analysis of protein fractions of bispecific single chain antibodies.
- Lane M Molecular weight marker
- Lane 1 cell culture supernatant
- lane 2 IMAC flow-through
- lane 3 IMAC eluate
- lane 4 purified antibody against CD19 and CD3 obtained from gel filtration (Sephadex 200).
- FIG. 5 Representative western blot analysis of purified bispecific single chain antibody fractions.
- Western blot analysis of purified bispecific protein was performed with antibodies directed against the HisTag (PentaHis, Qiagen) and goat anti mouse Ig labelled with alkaline phosphatase.
- Lane 1 cell culture supernatant;
- lane 2 IMAC flow-through;
- lane 3 IMAC eluate;
- lane 4 purified antibody against CD19 and CD3 obtained from gel filtration (Sephadex 200).
- Figure 6A Binding data for the anti-CD 19 (VL/VH) x anti-CD3 (VH/VL) construct as measured by FACS analysis on Nairn 6 (CD19+) and Jurkat (CD3+) cells.
- the left peak is the control; the right peak is the meacurement of the fluorescence shift for the binding specificity of interest.
- a shift to the right indicates binding of the construct to CD19 or CD3, respectively.
- Arrangement of VH and VL domains is indicated from N to C terminus (N->C).
- Figure 6B Binding data for the anti-CD19 (VH/VL) x anti-CD3 (VH/VL) construct as measured by FACS analysis on Nairn 6 (CD19+) and Jurkat (CD3+) cells.
- the left peak is the control; the right peak is the meacurement of the fluorescence shift for the binding specificity of interest.
- a shift to the right indicates binding of the construct to CD 19 or CD3, respectively.
- Arrangement of VH and VL domains is indicated from N to C terminus (N->C).
- Figure 6C Binding data for the anti-CD 19 (VL/VH) x anti-CD3 (VL/VH) construct as measured by FACS analysis on Nairn 6 (CD19+) and Jurkat (CD3+) cells.
- the left peak is the control; the right peak is the meacurement of the fluorescence shift for the binding specificity of interest.
- a shift to the right indicates binding of the construct to CD19 or CD3, respectively.
- Arrangement of VH and VL domains is indicated from N to C terminus (N->C).
- Figure 6D Binding data for the anti-CD3 (VH/VL) x anti-CD 19 (VH/VL) construct as measured by FACS analysis on Nairn 6 (CD 19+) and Jurkat (CD3+) cells.
- the left peak is the control; the right peak is the meacurement of the fluorescence shift for the binding specificity of interest.
- a shift to the right indicates binding of the construct to 5 CD19 or CD3, respectively.
- Arrangement of VH and VL domains is indicated from N to C terminus (N->C).
- Figure 6E Binding data for the anti-CD3 (VL/VH) x anti-CD 19 (VL/VH) construct as measured by FACS analysis on Nairn 6 (CD19+) and Jurkat (CD3+) cells.
- the left ) peak is the control; the right peak is the meacurement of the fluorescence shift for the binding specificity of interest.
- a shift to the right indicates binding of the construct to CD 19 or CD3, respectively.
- Arrangement of VH and VL domains is indicated from N to C terminus (N->C).
- FIG. 5 Figure 6F: Binding data for the anti-CD3 (VH/VL) x anti-CD19 (VL/VH) construct as measured by FACS analysis on Nairn 6 (CD 19+) and Jurkat (CD3+) cells.
- the left peak is the control; the right peak is the meacurement of the fluorescence shift for the binding specificity of interest.
- a shift to the right indicates binding of the construct to CD19 or CD3, respectively.
- Arrangement of VH and VL domains is indicated from N
- FIG. 7 Cytotoxicity data for selected domain-rearranged anti-CD3 / anti-CD 19 constructs.
- CB15 T cell clone and NALM6 cells were used in an E:T ratio of 1 :10.
- NALM6 target cells were labelled with calcein.
- Calcein release after cell lysis was 5 determined by FACS analysis.
- Figure 8 Binding of the 145-2C11 antibody to the recombinant, purified extracellular domain of the murine CD3 epsilon chain in ELISA.
- the ELISA was performed as described in Example 5, paragraph 1.
- the graph depicts absorption 3 values for antigen preparation or an irrelevant antigen binding to the coated 145- 2C11 antibody. Samples were done in 1 :5, 1:25 and 1:125 dilution.
- Figure 9 FACS binding-analysis of the 145-2C11 antibody on Jurkat cells transfected with the murine CD3 epsilon chain surface antigen.
- the FACS staining was performed as described in Example 5, paragraph 2.
- the filled histogram represents cells incubated with the isotype control.
- the open histogram shows cells incubated with the 145-2C11 antibody.
- Figure 10 FACS binding-analysis of the 145-2C11 antibody on untransfected Jurkat cells.
- the FACS staining was performed as described in Example 5, paragraph 2.
- the filled histogram represents cells incubated with the isotype control.
- the open histogram, superimposed on the filled histogram, represents cells incubated with the 145-2C11 antibody. 145-2C11 did not bind to Jurkat cells.
- Figure 11 FACS binding-analysis of the 145-2C11 antibody on CTLL2 cells.
- the FACS staining was performed as described in Example 5, paragraph 3.
- the filled histogram represents cells incubated with the isotype control.
- the open histogram indicates that the 145-2C11 antibody bound to CTLL2 cells.
- Example 1 Construction of CD19xCD3 and CD3xCD19 single chain bispecific antibodies comprising various domain rearrangements.
- bispecific single antibody chain molecules each comprising a domain with binding specificity for the human CD3 antigen as well as a domain with binding specificity for the human CD 19 antigen, were designed as set out in the following Table 1 :
- Table 1 Formats of bispecific single antibody chain molecules comprising anti-CD3 and anti-CD19 specificities
- variable light-chain (VL) and variable heavy-chain (VH) domains from the HD37 hybridoma were cloned according to standard PCR methods (Orlandi, Proc. Natl. Acad. Sci. USA 86 (1989), 3833-7).
- cDNA synthesis was carried out with oligo dT primers and Taq polymerase.
- the primers 5 ' L1 (SEQ ID NO: 37) and 3 ' K (SEQ ID NO: 38), flanking the VL domain, and 5 ⁇ 1 (SEQ ID NO: 39) and 3 ' G (SEQ ID NO: 40) for the heavy chain were used, based on primers described by D ⁇ bel, J. Immunol. Methods 175 (1994), 89-95.
- the cDNA of the anti- CD3 scFv fragment was kindly provided by Traunecker (Traunecker, EMBO J. 10 (1991) 3655-9).
- Construct 1 as set out in Table 1 was constructed as follows. To obtain an anti-CD 19 scFv-fragment, the corresponding VL- and VH-regions cloned into separate plasmid vectors, served as templates for a VL- and VH-specific PCR using the oligonucleotide primer pairs 5 ⁇ /LB5RRV (SEQ ID NO: 41) / 3 ⁇ /LGS15 (SEQ ID NO: 42) and 5VHGS15 (SEQ ID NO: 43) / 3 ' VHBspE1 (SEQ ID NO: 28), respectively.
- Overlapping complementary sequences were introduced into the PCR-products that combined to form the coding sequence of 15-amino acid (GIy Ser ⁇ ) 3 -linker during the subsequent fusion-PCR.
- This amplification step was performed with the primer pair 5 ⁇ LB5RRV (SEQ ID NO: 41) / 3NHBspE1 (SEQ ID NO: 28) and the resulting fusion product (or rather anti-CD19 scFv-fragment) was cleaved with the restriction enzymes EcoRV and BspE1 and thus cloned into the bluescript KS-vector (Statagene), containing the (EcoR1 /Sail -cloned) coding sequence of the anti-17- 1A/anti-CD3 bispecific single-chain antibody (actually the version without the Flag- tag) (Kufer, Cancer Immunol.
- the resulting plasmid-DNA was transfected into DHFR-deficient CHO-cells by electroporation. The selection, gene amplification and protein production were performed as previously described (Mack, Proc. Natl. Acad. Sci. USA 92 (1995), 7021-5).
- the DNA sequence corresponding to construct 1 as set out above in Table 1 is as represented in SEQ ID NO: 29.
- the protein translation of this DNA sequence (without leader but including the stop codon) is as represented in SEQ ID NO: 30.
- PCR with the respective primer combination 5 ' VHCD19BsrGI (SEQ ID NO: 24) and 3 ⁇ /HCD19GS15 (SEQ ID NO: 25) or 5NLCD19GS15 (SEQ ID NO: 26) and 3 ' VLCD19BspEI (SEQ ID NO: 27) was used. During these PCR cycles overlapping complementary sequences were introduced into the PCR-products forming the coding sequence of a 15 amino acid linker during the subsequent fusion PCR.
- the amplified VL and VH domains were fused in a second PCR reaction (fusion PCR) in which only the outer primers, namely 5 ' VHCD19BsrGI (SEQ ID NO: 24) and 3 ' VLCD19BspEI (SEQ ID NO: 27), and both amplificants were required.
- fusion PCR a second PCR reaction
- a similar procedure employing other combinations of primers was used to construct other domain arrangements.
- a set of appropriate primers was designed to perform multiple PCR-based cloning steps, finally resulting in the various VL-VH domain arrangements.
- the primer combinations used are listed in the following table:
- Table 2 Overview of PCR-based cloning steps used for construction of positions A1 and A2 of constructs 2, 3, 4, 5, 6, 7 and 8 as shown in Table 1
- Table 3 Overview of PCR-based cloning steps used for construction of positions B1 and B2 of constructs 2, 3, 4, 5, 6, 7 and 8 as shown in Table 1
- the corresponding PCR product which was flanked by two BspEI sites, was cloned into a plasmid designated BS-CTI, which was digested with BspEI and Xmal restriction enzymes.
- a polylinker designated CTI (SEQ ID NO: 36) was inserted before into the Bluescript KS vector (GenBank accession number X52327) using the restriction enzyme cleavage sites Xbal and Sail in order to provide additional cleavage sites as well as the sequence encoding a G 4 S linker, six consecutive histidine residues and a stop codon.
- the BspEI site of the VH domain was fused with the Xmal site of the plasmid thereby destroying both sites.
- the correct orientation of the variable domain was verified by sequencing according to standard protocols.
- DNA encoding the single chain bispecific antibodies in Table 1 (SEQ ID NOs: 29, 1 , 3, 5, 7, 9, 11, 13) were transfected into DHFR deficient CHO cells for eukaryotic protein expression in DHFR deficient CHO cells as described in Mack et al. (Mack, Proc Natl Acad Sci USA 92 (1995), 7021-25). Gene amplification of the construct was induced by increasing concentrations of methotrexate (MTX) up to a final concentration of 20 nM MTX. The transfected cells were then expanded and 1 liter of supernatant produced.
- MTX methotrexate
- Example 2 Expression and purification of the single chain bispecific antibodies directed against CD3 and CD 19
- the protein was expressed in Chinese hamster ovary cells (CHO). Transfection of the expression vector was performed following calcium phosphate treatment of the cells ("Molecular Cloning", Sambrook et. al. 1989). The cells were grown in roller bottles with CHO modified DMEM medium (HiQ®, HiClone) for 7 days before harvest. The cells were removed by centrifugation and the supernatant containing the expressed protein was stored at -20°C.
- Akta® FPLC System (Pharmacia) and Unicorn® Software were used for chromatography. All chemicals were of research grade and purchased from Sigma (Deisenhofen) or Merck (Darmstadt). Immobilized metal affinity chromatography ("IMAC") was performed using a Fractogel® column (Merck) which was loaded with ZnCI 2 according to the protocol provided by the manufacturer. The column was equilibrated with buffer A2 (20 mM sodium phosphate buffer pH 7.5, 0.4 M NaCl) and the cell culture supernatant (500 ml) was applied to the column (10 ml) at a flow rate of 3 ml/min. The column was washed with buffer A2 to remove unbound sample.
- buffer A2 20 mM sodium phosphate buffer pH 7.5, 0.4 M NaCl
- Bound protein was eluted using a 2 step gradient of buffer B2 (20 mM sodium phosphate buffer pH 7.5, 0.4 M NaCl, 0.5 M Imidazol) according to the following:
- Step 1 20% buffer B2 in 6 column volumes
- Step 2 100% buffer B2 in 6 column volumes.
- Eluted protein fractions from step 2 were pooled for further purification.
- the single chain bispecific antibodies were isolated in a two step purification process of IMAC ( Figure 2) and gel filtration ( Figure 3).
- the main product had a molecular weight of ca. 52 kDa under native conditions as determined by gel filtration in PBS. This molecular weight corresponds to the single chain bispecific antibody. All constructs were purified according to this method. Construct #4 could not be purified from cell culture supernatants due to extremely low levels of specific protein expressed and secreted into the supernatant.
- Purified bispecific protein was analyzed in SDS PAGE under reducing conditions performed with pre-cast 4-12% Bis Tris gels (Invitrogen). Sample preparation and application were performed according to the protocol provided by the manufacturer. The molecular weight was determined with MultiMark protein standard (Invitrogen). The gel was stained with colloidal Coomassie (Invitrogen protocol). The purity of the isolated protein was >95% as determined by SDS-PAGE ( Figure 4; protein band at 52 kD).
- Western Blot was performed using an Optitran® BA-S83 membrane and the Invitrogen Blot Module according to the protocol provided by the manufacturer.
- the antibodies used were directed against the His Tag (Penta His, Qiagen) and Goat- anti-mouse Ig labeled with alkaline phosphatase (AP) (Sigma), and BCIP/NBT (Sigma) as substrate.
- the single chain bispecific antibody could be specifically detected by Western Blot ( Figure 5). A single band was detected at 52 kD corresponding to the purified bispecific molecule.
- Example 3 Flow cvtometric binding analysis of CD19xCD3 specific polypeptides
- a FACS analysis was performed.
- CD19 positive Nairn 6 cells human B cell precursor leukemia
- CD3 positive Jurkat cells human T cell leukemia
- 200,000 Nairn 6 cells and 200,000 Jurkat cells were respectively incubated for 30 min on ice with 50 ⁇ l of the pure cell supernatant of CHO cell cultures each expressing bispecific antibodies with different arrangements of VH and VL domains of CD19 and CD3 (as described in Example 2).
- the cells were washed twice in PBS and binding of the construct was detected as follows.
- the cells treated as described above were contacted with an unlabeled murine Penta His antibody (diluted 1 :20 in 50 ⁇ l PBS with 2% FCS; Qiagen; Order No. 34660), which specifically binds to cell-bound construct via the construct's C- terminal histidine tag.
- a washing step followed to remove unbound murine Penta His antibody.
- Bound anti His antibodies were detected with an Fc gamma-specific antibody (Dianova, order no. 115-116-071) conjugated to phycoerythrin, diluted 1:100 in 50 ⁇ l PBS with 2% FCS (thick grey line in Figures 6A-6F).
- As a negative control (thin black line in Figures 6A-6F) fresh culture medium was used in place of culture supernatant.
- Cytotoxic activity of the bispecific antibodies with rearranged VH and VL domains was determined in a fluorochrome release based cytotoxicity assay.
- CD19 positive NALM6 cells were used as target cells (1.5x10 7 ) labeled with 10 ⁇ M calcein AM (Molecular Probes, Leiden, Netherland, no. C-1430) for 30 min at 37°C in cell culture medium. After two washes in cell culture medium, cells were counted and mixed with the CD4-positive T cell clone CB15 cells (kindly provided by Dr. Fickenscher, University of Er Weg/Nuernberg, Germany). 2 x 10 6 CB15 cells and 2 x 10 5 Nalm6 cells were mixed per ml (E:T ratio of 1:10) and 50 ⁇ l of this suspension was used per well in a 96 well round bottom plate.
- Antibodies were diluted in RPMI/10% FCS to the required concentration and 50 ⁇ l of this solution was added to the cell suspension. A standard reaction was incubated at 37°C/5% C0 2 for 2 hours. After the cytotoxic reaction, the released dye in the incubation medium can be quantitated in a fluorescence reader (Tecan, Crailsheim, Germany) and compared with the fluorescence signal from a control reaction (without bispecific antibody), and the fluorescence signal obtained for totally lysed cells (for 10 min in 1% saponin).
- Sigmoidal dose response curves typically had R 2 values >0.97 as determined by Prism Software (GraphPad Software Inc., San Diego, USA). EC 5 o values calculated by the analyis program were used for comparison of bioactivity.
- constructs #2, 6, 8 and 1 show cytotoxic activity against CD19 expressing NALM 6 cells. Strongest bioactivity was observed for constructs #2, 6, 8 and 1. Strong cytotoxic activity with EC 50 values ⁇ 500 pg/ml was detected for constructs #2, 6, 8 and 1. In addition to their high bioactivity, constructs #2 and #6 are also especially amenable to inclusion in pharmaceutical compositions. Constructs #3 and #7 showed EC 50 values of 52 ng/ml and 31 ng/ml respectively.
- Example 5 The 145-2C11 antibody
- the monoclonal antibody 145-2C11 directed against murine CD3 was analysed in different assays in order to characterize this antibody as group I or II anti-CD3 antibody.
- 145-2C11 was used by Brissinck, 1991 , J.Immunol. 147-4019 for constructing a bispecific antibody directed against BCL-1 and murine CD3 and also by de Jonge, 1997, Cancer Immunol. Immunother. 45-162.
- the anti-murine CD3 epsilon antibody (145-2C11 BD biosciences, Heidelberg, FRG) was coated (50 ⁇ l at 5 ⁇ g/ml in PBS) on a Maxisorp ELISA plate (Nunc GmbH, Wiesbaden, FRG). After overnight incubation unspecific binding was blocked with 1 ,5% BSA in PBS for 1 hour. After washing three times with 200 ⁇ l PBS, different dilutions of the recombinant C-terminally His6-tagged CD3 protein (obtained by a procedure analogous to that described in Example 6 for obtaining recombinant human CD3-epsilon) and an irrelevant antigen (BSA) were incubated for 1 hour in the prepared cavities of the plate.
- BSA irrelevant antigen
- Binding of recombinant CD3 was detected with horseradish peroxidase conjugated anti-His antibody (Roche Diagnostics GmbH, Mannheim, FRG; diluted 1 :500 in 1 ,5% BSA in PBS) binding to a polyhistidine tag.
- ABTS 2,2'-Azino-di[3-ethylbenzthiazoline sulfonate (6)] diammonium salt, Roche Diagnostics GmbH, Mannheim, FRG
- the absorbance values were measured on a SPECTRAFIuor Plus photometer (Tecan GmbH, Crailsheim). The measurement wavelength was 405 nm, the reference wavelength was 620 nm.
- Binding of 145-2C11 antibody to Jurkat cells (obtained from ATCC) transfected with the murine CD3 epsilon chain surface antigen was tested using an FACS assay. To this end, 2.5x10 5 cells were incubated with a 1 :50 dilution of the PE-conjugated 145- 2C11 antibody (BD biosciences, Heidelberg, FRG) in 50 ⁇ l PBS with 2%FCS. As a control another sample of cells was incubated with a 1 :50 dilution of a PE-conjugated hamster IgG groupl Kappa isotype control (BD biosciences, Heidelberg, FRG) in 50 ⁇ l PBS with 2%FCS.
- Untransfected cells were also assayed under the described conditions. The samples were measured on a FACSscan (BD biosciences, Heidelberg, FRG). Specific binding of the 145-2C11 antibody as compared to the isotype control was clearly detectable on the transfected but not on the untransfected cells ( Figures 9 and 10) inducing a shift in fluorescence intensity.
- murine anti CD3 antibody 145-2C11 recognized purified recombinant CD3 epsilon as well as murine CD3 epsilon expressed in eukaryotic cells. 145-2C11 bound to Jurkat cells transfected with murine CD3 epsilon as well as to a murine T cell line expressing the CD3 epsilon chain in its native murine TCR receptor complex. Both cell lines express CD3 epsilon on the cell surface in the context of other TCR subunits.
- CD3-reactive bispecific single-chain antibodies may be assigned to different CD3- binding patterns according to the classification of Tunnacliffe, International Immunology 1 (1989), 546.
- an ELISA may be carried out with purified recombinant human CD3-epsilon.
- Recombinant human CD3-epsilon may be e.g. obtained as C-kappa-fusion construct as described by Tunnacliffe, Immunol. Lett. 21 (1989) 243 or as truncated soluble CD3-epsilon available according to the following procedure:
- cDNA was isolated from human peripheral blood mononuclear cells. Preparation of the cells was performed according to standard protocols (Current Protocols in Immunology (Coligan, Kruisbeek, Margulies, Shevach and Strober, John Wiley & Sons, Inc., USA, 2002)). The isolation of total RNA and cDNA synthesis by random- primed reverse transcription was performed according to standard protocols (Sambrock, Molecular Cloning; Laboratory Manual, 2nd edition, Cold Spring Harbor laboratory Press, Cold Spring Harbor, New York (1989)). PCR was used to amplify the coding sequence of the extracellular domain of the human CD3 epsilon chain.
- the primers used in the PCR were designed so as to introduce restriction sites at the beginning and the end of the cDNA coding for the extracellular portion of the human CD3 epsilon chain (SEQ ID NO: 80 and SEQ ID NO:81).
- the introduced restriction sites, BsrGI and BspEI were utilised in the following cloning procedures.
- the PCR product was then cloned via BsrGI and BspEI into a plasmid designated BS-Fss-Lsp derived from the Bluescript KS + cloning vector (Stratagene Europe, Amsterdam- Zuiddoost, the Netherlands) following standard protocols.
- the vector was generated by cloning a DNA fragment (SEQ ID NO: 82) via EcoRI and Sail into Bluescript KS + .) The sequence of different clones was determined by sequencing according to standard protocols. By cloning into BS-Fss-Lsp the coding sequence of a murine immunoglobulin heavy chain leader peptide was fused in-frame to the 5' end of the coding sequence for the extracellular portion of the human CD3 epsilon chain.
- the cDNA was then cloned via EcoRI and BspEI into another plasmid designated as BSCTI to attach a sequence to the C-terminus, coding for a polyhistidine tag of six consecutive histidine residues followed by a stop codon (BSCTI is described in Kufer, Cancer Immunity 1 (2001), 10).
- BSCTI Bacillus subtilis
- the BspEI site of the cDNA was fused into an Xmal site of the plasmid thereby destroying both sites. All cloning steps were designed so as to generate an intact reading frame for the construct.
- the plasmid now contained a sequence coding for a protein comprising a murine immunoglobulin heavy chain leader peptide, to allow for secreted expression, followed by the extracellular domain of the human CD3 epsilon chain followed by a polyhistidine tag of six consecutive histidine residues, to allow for purification and detection via the polyhistidine tag (SEQ ID NO: 78 and SEQ ID NO: 79).
- This sequence was then cloned into the plasmid pFastBadTM (Invitrogen GmbH, Düsseldorf, FRG) via EcoRI and Sail.
- an anti-human CD3 epsilon antibody (UCHT1 BD biosciences, Heidelberg, FRG) was coated (50 ⁇ l at 5 ⁇ g/ml in PBS) on a Maxisorp ELISA plate (Nunc GmbH, Wiesbaden, FRG) overnight. Unspecific binding was blocked with 1.5 % BSA in PBS for 1 hour. All prior and subsequent washing steps were performed three times with 200 ⁇ l PBS. Afterwards, eluate fractions were incubated for 1 hour in the prepared cavities of the plate.
- Detection of the recombinant protein was performed with a horseradish peroxidase conjugated anti-His antibody (Roche Diagnostics GmbH, Mannheim, FRG; 50 ⁇ l of antibody diluted 1:500 in 1.5 % BSA in PBS). Development of the ELISA was performed with ABTS (2,2'-Azino-bis(3-Ethylbenz-Thiazolin)-6- Sulfonic acid) Roche Diagnostics GmbH, Mannheim, FRG) according to the specifications of the manufacturer. Positive fractions were further purified over a cobalt-chelate column which preferentially binds histidine-tagged proteins. Eluate fractions were tested using the described ELISA assay. Positive fractions were pooled and concentrated.
- purified recombinant human CD3-epsilon may be coated (50 ⁇ l at 10 ⁇ g/ml in PBS) on a Maxisorp ELISA plate (Nunc GmbH, Wiesbaden, FRG) overnight and unspecific binding subsequently blocked with 1 ,5% BSA in PBS for 1 hour. Next the ELISA wells are washed three times with 200 ⁇ l PBS.
- CD3-reactive bispecific single-chain antibody 50 ⁇ l at 10 ⁇ g/ml in 1,5% BSA in PBS
- a version that (i) contains an N-terminal FLAG-tag with the amino acid sequence: dykddddk (obtainable e.g. as described in Mack, PNAS 92 (1995) 7021) but (ii) avoids a polyhistidine tag can be incubated for 1 hour on immobilized CD3-epsilon.
- negative control 50 ⁇ l 1,5% BSA in PBS without bispecific single-chain antibody may be used.
- the "group I” anti-CD3 antibody UCHT1 (BD biosciences, Heidelberg, FRG; 50 ⁇ l of antibody diluted to 5 ⁇ g/ml in 1,5% BSA in PBS) may be incubated on immobilized CD3-epsilon.
- bispecific single-chain antibody specifically bound to human CD3-epsilon can be detected with an unconjugated anti-FLAG antibody (ANTI-FLAG M2 obtained from Sigma-Aldrich Chemie GmbH, Taufkirchen FRG; 50 ⁇ l of antibody diluted to 5 ⁇ g/ml in 1 ,5% BSA in PBS) followed by a horseradish peroxidase- conjugated, goat anti-mouse IgG, Fc-gamma fragment specific antibody (obtained from Dianova, Hamburg, FRG; diluted 1 :1000 in 50 ⁇ l PBS with 1 ,5% BSA), which directly detects the control antibody bound to immobilized CD3-epsilon.
- ANTI-FLAG M2 obtained from Sigma-Aldrich Chemie GmbH, Taufmün FRG; 50 ⁇ l of antibody diluted to 5 ⁇ g/ml in 1 ,5% BSA in PBS
- CD3-binding patterns may be carried out by flowcytometric binding analysis of CD3-reactive bispecific single-chain antibodies on human T cells and human CD3-epsilon-transgenic murine T cells as described e.g. in Tunnacliffe, International Immunology 1(1989) 546.
- Flowcytometry may be carried out as described in Example 3 of the present invention if the bispecific single-chain antibody to be analyzed carries a polyhistidine-tag or according to the same protocol, except that the detection antibody is replaced by a fluorescence-labeled anti-Flag antibody if the bispecific single-chain antibody is Flag-tagged.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006529929A JP2008501621A (en) | 2003-05-31 | 2004-05-26 | Pharmaceutical composition comprising a bispecific anti-CD3, anti-CD19 antibody construct for treating a B cell related disease |
AU2004242846A AU2004242846A1 (en) | 2003-05-31 | 2004-05-26 | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
US10/554,852 US7635472B2 (en) | 2003-05-31 | 2004-05-26 | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
EP04739378.0A EP1629012B1 (en) | 2003-05-31 | 2004-05-26 | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
CA2522586A CA2522586C (en) | 2003-05-31 | 2004-05-26 | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03012136.2 | 2003-05-31 | ||
EP03012136 | 2003-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004106381A1 true WO2004106381A1 (en) | 2004-12-09 |
Family
ID=33483898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/005685 WO2004106381A1 (en) | 2003-05-31 | 2004-05-26 | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
Country Status (9)
Country | Link |
---|---|
US (1) | US7635472B2 (en) |
EP (1) | EP1629012B1 (en) |
JP (3) | JP2008501621A (en) |
CN (1) | CN100509850C (en) |
AU (1) | AU2004242846A1 (en) |
CA (1) | CA2522586C (en) |
RU (1) | RU2005141512A (en) |
WO (1) | WO2004106381A1 (en) |
ZA (1) | ZA200508280B (en) |
Cited By (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005077982A1 (en) * | 2004-02-16 | 2005-08-25 | Micromet Ag | Less immunogenic binding molecules |
WO2007068354A1 (en) | 2005-12-16 | 2007-06-21 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
WO2010037835A2 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
WO2010037838A2 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
WO2010037837A2 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
WO2010052013A1 (en) | 2008-11-07 | 2010-05-14 | Micromet Ag | Treatment of pediatric acute lymphoblastic leukemia |
WO2010052014A1 (en) | 2008-11-07 | 2010-05-14 | Micromet Ag | Treatment of acute lymphoblastic leukemia |
WO2010037836A3 (en) * | 2008-10-01 | 2010-07-22 | Micromet Ag | Cross-species-specific psmaxcd3 bispecific single chain antibody |
WO2011051307A1 (en) | 2009-10-27 | 2011-05-05 | Micromet Ag | Dosage regimen for administering a cd19xcd3 bispecific antibody |
EP2383297A1 (en) | 2006-08-14 | 2011-11-02 | Xencor Inc. | Optimized antibodies that target CD19 |
CN102250245A (en) * | 2010-05-27 | 2011-11-23 | 四川大学 | Bispecific antibody capable of resisting B cell lymphoma and application thereof |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
WO2012055961A1 (en) | 2010-10-27 | 2012-05-03 | Micromet Gmbh | Means and methods for treating dlbcl |
WO2012062596A1 (en) | 2010-11-10 | 2012-05-18 | Micromet Gmbh | Prevention of adverse effects caused by cd3 specific binding domains |
WO2012066058A1 (en) | 2010-11-16 | 2012-05-24 | Boehringer Ingelheim International Gmbh | Agents and methods for treating diseases that correlate with bcma expression |
WO2012146394A1 (en) | 2011-04-28 | 2012-11-01 | Amgen Research (Munich) Gmbh | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
US8604177B2 (en) | 2006-09-08 | 2013-12-10 | Abbvie Inc. | Interleukin-13 binding proteins |
US8629257B2 (en) | 2005-06-30 | 2014-01-14 | Abbvie Inc. | IL-12/p40 binding proteins |
WO2014011988A3 (en) * | 2012-07-13 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
US8709421B2 (en) | 2005-04-26 | 2014-04-29 | Trion Pharma Gmbh | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
WO2014122251A2 (en) | 2013-02-08 | 2014-08-14 | Amgen Research (Munich) Gmbh | Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains |
WO2015095410A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
WO2015095418A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
EP2714733A4 (en) * | 2011-05-21 | 2015-10-14 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
US9187564B2 (en) | 2010-10-05 | 2015-11-17 | Hoffmann-La Roche Inc. | Antibodies against human TWEAK and uses thereof |
WO2015181683A1 (en) | 2014-05-30 | 2015-12-03 | Amgen Research (Munich) Gmbh | Risk-stratification of b-precursor acute lymphoblastic leukemia patients |
WO2016073794A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
WO2016073791A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
WO2016127043A1 (en) * | 2015-02-05 | 2016-08-11 | Stc.Unm | Anti-pre-bcr antagonists and methods |
EP3064507A1 (en) | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
JP2016526915A (en) * | 2013-08-06 | 2016-09-08 | シェンジェン インスティテュート オブ アドバーンスド テクノロジー | Mini-circle DNA recombination parent plasmid having genetically engineered antibody gene expression cassette, mini-circle DNA having the expression cassette and use [see related applications] This application is named “Gene engineered antibody gene expression” Claiming the priority of Chinese patent application 2013103399305.0 filed on Aug. 06, 2013, entitled "Minicircle DNA recombinant parent plasmid with cassette, minicircle DNA with its expression cassette and use" The entire contents are hereby incorporated by reference. |
AU2013202375B2 (en) * | 2005-12-16 | 2016-10-27 | Amgen Research (Munich) Gmbh | Means and Methods for the Treatment of Tumorous Diseases |
US9486475B2 (en) | 2013-02-08 | 2016-11-08 | Amgen Research (Munich) Gmbh | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
WO2016196381A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Pd-l1 promoter methylation in cancer |
WO2016205320A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
WO2017055314A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-cd19xcd3 t cell activating antigen binding molecules |
WO2017096368A1 (en) * | 2015-12-04 | 2017-06-08 | Macrogenics, Inc. | Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
WO2017129585A1 (en) * | 2016-01-25 | 2017-08-03 | Amgen Research (Munich) Gmbh | Pharmaceutical composition comprising bispecific antibody constructs |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
WO2018029124A1 (en) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
US9908937B2 (en) | 2008-07-18 | 2018-03-06 | Bristol-Myers Squibb Company | Compositions monovalent for CD28 binding and methods of use |
US9987231B2 (en) | 2011-12-28 | 2018-06-05 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
WO2018114748A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists |
WO2018114754A1 (en) | 2016-12-19 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
WO2018184966A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Antibodies binding to steap-1 |
WO2018220099A1 (en) | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
US10174095B2 (en) | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
US10202452B2 (en) | 2012-04-20 | 2019-02-12 | Aptevo Research And Development Llc | CD3 binding polypeptides |
WO2019075366A1 (en) | 2017-10-13 | 2019-04-18 | Merck Sharp & Dohme Corp. | Compositions and methods for treating diffuse large b cell lymphoma |
WO2019086497A2 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Combination therapy with targeted ox40 agonists |
WO2019126634A2 (en) | 2017-12-22 | 2019-06-27 | Genentech, Inc. | Targeted integration of nucleic acids |
WO2019122052A2 (en) | 2017-12-21 | 2019-06-27 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a2/wt1 |
WO2019140196A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Anti-pd-1 antibodies and methods of treatment |
WO2019149715A1 (en) | 2018-01-31 | 2019-08-08 | F. Hoffmann-La Roche Ag | Stabilized immunoglobulin domains |
WO2019149716A1 (en) | 2018-01-31 | 2019-08-08 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
WO2019154890A1 (en) | 2018-02-09 | 2019-08-15 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
WO2019175071A1 (en) | 2018-03-13 | 2019-09-19 | F. Hoffmann-La Roche Ag | Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies |
WO2019175125A1 (en) | 2018-03-13 | 2019-09-19 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
WO2019191552A1 (en) | 2018-03-29 | 2019-10-03 | Genentech, Inc. | Modulating lactogenic activity in mammalian cells |
WO2019202041A1 (en) | 2018-04-18 | 2019-10-24 | F. Hoffmann-La Roche Ag | Multispecific antibodies and use thereof |
CN110577603A (en) * | 2019-08-15 | 2019-12-17 | 北京东方百泰生物科技有限公司 | anti-CD 3 and anti-CD 19 bispecific antibody |
US10568947B2 (en) | 2014-07-21 | 2020-02-25 | Novartis Ag | Treatment of cancer using a CLL-1 chimeric antigen receptor |
WO2020061349A1 (en) | 2018-09-21 | 2020-03-26 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
WO2020058297A1 (en) | 2018-09-18 | 2020-03-26 | F. Hoffmann-La Roche Ag | Use of a cathepsin s inhibitor against the formation of anti-drug antibodies |
US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
WO2020096959A1 (en) | 2018-11-05 | 2020-05-14 | Genentech, Inc. | Methods of producing two chain proteins in prokaryotic host cells |
WO2020132165A1 (en) | 2018-12-21 | 2020-06-25 | Genentech, Inc. | Targeted integration of nucleic acids |
WO2020127619A1 (en) | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
WO2020141145A1 (en) | 2018-12-30 | 2020-07-09 | F. Hoffmann-La Roche Ag | Anti-rabbit cd19 antibodies and methods of use |
WO2020154410A1 (en) | 2019-01-23 | 2020-07-30 | Genentech, Inc. | Methods of producing multimeric proteins in eukaryotic host cells |
WO2020221792A1 (en) | 2019-04-30 | 2020-11-05 | Amgen Research (Munich) Gmbh | Means and methods of treating burkitt lymphoma or leukemia |
WO2021018925A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
WO2021018859A2 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
WO2021055577A2 (en) | 2019-09-18 | 2021-03-25 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
WO2021041300A3 (en) * | 2019-08-23 | 2021-04-01 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
US10988517B2 (en) * | 2019-01-07 | 2021-04-27 | Shattuck Labs, Inc. | Heterodimeric proteins for modulating gamma delta T cells |
WO2021122875A1 (en) | 2019-12-18 | 2021-06-24 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a2/mage-a4 |
WO2021133723A2 (en) | 2019-12-23 | 2021-07-01 | Genentech, Inc. | Apolipoprotein l1-specific antibodies and methods of use |
WO2021146328A1 (en) | 2020-01-13 | 2021-07-22 | Aptevo Research And Development Llc | Formulations for protein therapeutics |
WO2021146336A1 (en) | 2020-01-13 | 2021-07-22 | Aptevo Research And Development Llc | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
EP3862365A1 (en) | 2016-01-08 | 2021-08-11 | F. Hoffmann-La Roche AG | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
WO2021183207A1 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER |
WO2021195464A2 (en) | 2020-03-26 | 2021-09-30 | Genentech, Inc. | Modified mammalian cells |
WO2021214277A1 (en) | 2020-04-24 | 2021-10-28 | F. Hoffmann-La Roche Ag | Enzyme and pathway modulation with sulfhydryl compounds and their derivatives |
WO2021249990A2 (en) | 2020-06-08 | 2021-12-16 | Hoffmann-La Roche Inc. | Anti-hbv antibodies and methods of use |
WO2021255155A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cd19 |
WO2021255142A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
WO2021255143A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and folr1 |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
WO2021257503A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
WO2021262783A1 (en) | 2020-06-24 | 2021-12-30 | Genentech, Inc. | Apoptosis resistant cell lines |
WO2021262798A1 (en) | 2020-06-24 | 2021-12-30 | Genentech, Inc. | Targeted integration of nucleic acids |
WO2022016037A1 (en) | 2020-07-17 | 2022-01-20 | Genentech, Inc. | Anti-notch2 antibodies and methods of use |
WO2022018262A1 (en) * | 2020-07-24 | 2022-01-27 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
WO2022047222A2 (en) | 2020-08-28 | 2022-03-03 | Genentech, Inc. | Crispr/cas9 multiplex knockout of host cell proteins |
US11286300B2 (en) | 2015-10-01 | 2022-03-29 | Hoffmann-La Roche Inc. | Humanized anti-human CD19 antibodies and methods of use |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
WO2022129120A1 (en) | 2020-12-17 | 2022-06-23 | F. Hoffmann-La Roche Ag | Anti-hla-g antibodies and use thereof |
EP4026848A1 (en) | 2015-12-09 | 2022-07-13 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing the cytokine release syndrome |
WO2022169825A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
WO2022169872A1 (en) | 2021-02-03 | 2022-08-11 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
US11440972B2 (en) | 2017-08-01 | 2022-09-13 | Ab Studio Inc. | Bispecific antibodies and uses thereof |
WO2022192647A1 (en) | 2021-03-12 | 2022-09-15 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
WO2022225880A1 (en) | 2021-04-19 | 2022-10-27 | Genentech, Inc. | Modified mammalian cells |
WO2022226317A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
WO2022228706A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
WO2022246244A1 (en) | 2021-05-21 | 2022-11-24 | Aptevo Research And Development Llc | Dosing regimens for protein therapeutics |
WO2022246259A1 (en) | 2021-05-21 | 2022-11-24 | Genentech, Inc. | Modified cells for the production of a recombinant product of interest |
US11535666B2 (en) * | 2016-12-30 | 2022-12-27 | Cytocares (Shanghai) Inc. | Trifunctional molecule and application thereof |
US11541103B2 (en) | 2017-08-03 | 2023-01-03 | Amgen Inc. | Interleukin-21 mutein/ anti-PD-1 antibody conjugates |
EP4116427A1 (en) | 2012-05-17 | 2023-01-11 | Kymab Limited | In vivo guided selection & antibodies |
WO2023280227A2 (en) | 2021-07-06 | 2023-01-12 | Profoundbio Us Co. | Linkers, drug linkers and conjugates thereof and methods of using the same |
WO2023287663A1 (en) | 2021-07-13 | 2023-01-19 | Genentech, Inc. | Multi-variate model for predicting cytokine release syndrome |
WO2023001884A1 (en) | 2021-07-22 | 2023-01-26 | F. Hoffmann-La Roche Ag | Heterodimeric fc domain antibodies |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
US11597759B2 (en) | 2017-06-21 | 2023-03-07 | Gilead Sciences, Inc. | Multispecific antibodies that target HIV GP120 and CD3 |
WO2023062188A1 (en) | 2021-10-15 | 2023-04-20 | Amgen Research (Munich) Gmbh | Subcutaneous administration of cd19-binding t cell engaging antibodies |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
WO2023104938A1 (en) | 2021-12-10 | 2023-06-15 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and plap |
US11685781B2 (en) | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
WO2023141445A1 (en) | 2022-01-19 | 2023-07-27 | Genentech, Inc. | Anti-notch2 antibodies and conjugates and methods of use |
US11713358B2 (en) | 2015-08-28 | 2023-08-01 | Amunix Pharmaceuticals, Inc. | Chimeric polypeptide assembly and methods of making and using the same |
WO2023180353A1 (en) | 2022-03-23 | 2023-09-28 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
US11795226B2 (en) | 2017-12-12 | 2023-10-24 | Macrogenics, Inc. | Bispecific CD16-binding molecules and their use in the treatment of disease |
US11827713B2 (en) | 2017-06-27 | 2023-11-28 | Nanjing Legend Biotech Co., Ltd. | Chimeric antibody immune effector cell engagers and methods of use thereof |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
US11939389B2 (en) | 2018-06-13 | 2024-03-26 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
Families Citing this family (159)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID27512A (en) * | 1998-04-21 | 2001-04-12 | Microment Ges Fur Biomedizinis | PRIVATE POLIPEPTIDES CD19XCD3 AND ITS USES |
US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
DE10254601A1 (en) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Gene products differentially expressed in tumors and their use |
EP2292664B1 (en) | 2003-10-16 | 2016-11-23 | Amgen Research (Munich) GmbH | Multispecific deimmunized CD3-binders |
US8603824B2 (en) | 2004-07-26 | 2013-12-10 | Pfenex, Inc. | Process for improved protein expression by strain engineering |
KR101456728B1 (en) * | 2006-09-08 | 2014-10-31 | 메디뮨 엘엘씨 | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
EP2142651B1 (en) | 2007-04-27 | 2013-05-22 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
HUE031533T2 (en) * | 2007-10-19 | 2017-07-28 | Seattle Genetics Inc | Cd19 binding agents and uses thereof |
WO2009070642A1 (en) * | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
US9029508B2 (en) * | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN102112494A (en) * | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | Dual variable domain immunoglobulins and uses thereof |
EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
KR20110031369A (en) * | 2008-07-08 | 2011-03-25 | 아보트 러보러터리즈 | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
JP2013503607A (en) * | 2009-09-01 | 2013-02-04 | アボット・ラボラトリーズ | Dual variable domain immunoglobulins and uses thereof |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
AR078651A1 (en) * | 2009-10-15 | 2011-11-23 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
CN103124743A (en) | 2009-12-29 | 2013-05-29 | 新兴产品开发西雅图有限公司 | RON binding constructs and methods of use thereof |
DK3029066T3 (en) | 2010-07-29 | 2019-05-20 | Xencor Inc | ANTIBODIES WITH MODIFIED ISOELECTRIC ITEMS |
NZ607480A (en) | 2010-08-03 | 2014-10-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
EP2608803A4 (en) | 2010-08-26 | 2014-01-15 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
DK2635607T3 (en) | 2010-11-05 | 2019-11-18 | Zymeworks Inc | STABLE HETERODIMED ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN |
US20140056897A1 (en) | 2011-03-10 | 2014-02-27 | Hco Antibody, Inc. | Bispecific three-chain antibody-like molecules |
CA2850291A1 (en) * | 2011-09-29 | 2013-04-04 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
ES2899956T3 (en) | 2011-11-04 | 2022-03-15 | Zymeworks Inc | Stable heterodimeric antibody design with mutations in the Fc domain |
EP2797955A2 (en) | 2011-12-30 | 2014-11-05 | AbbVie Inc. | Dual variable domain immunoglobulins against il-13 and/or il-17 |
SG10201705698PA (en) | 2012-01-13 | 2017-08-30 | Apo-T B V | Aberrant Cell-Restricted Immunoglobulins Provided With A Toxic Moiety |
US9499634B2 (en) | 2012-06-25 | 2016-11-22 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
SG11201503412RA (en) | 2012-11-01 | 2015-05-28 | Abbvie Inc | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
KR102643443B1 (en) * | 2012-11-13 | 2024-03-06 | 비온테크 에스이 | Agents for treatment of claudin expressing cancer diseases |
CA2892059C (en) * | 2012-11-21 | 2023-02-14 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
EP2943511B1 (en) | 2013-01-14 | 2019-08-07 | Xencor, Inc. | Novel heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
CA2906927C (en) | 2013-03-15 | 2021-07-13 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
MX2015013166A (en) | 2013-03-15 | 2015-12-11 | Abbvie Inc | Dual specific binding proteins directed against il-1 beta and il-17. |
US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
EP3620470B1 (en) | 2013-10-11 | 2023-07-26 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Tem8 antibodies and their use |
EP3074424A4 (en) | 2013-11-27 | 2017-06-14 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting her2 |
WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
CN106062206A (en) * | 2014-01-15 | 2016-10-26 | 酵活有限公司 | Bi-specific cd3 and cd19 antigen-binding constructs |
WO2015121383A1 (en) | 2014-02-12 | 2015-08-20 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
MX2016012578A (en) | 2014-03-28 | 2017-04-13 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3. |
CN105017422A (en) * | 2014-04-30 | 2015-11-04 | 山东百因制药技术有限公司 | Anti-CD3/anti-CD19 dual-specific antibody and application thereof |
PE20170286A1 (en) | 2014-07-01 | 2017-03-30 | Pfizer | BISPECIFIC HETERODIMERIC DIACBODIES AND THEIR USES |
US9611325B2 (en) | 2014-07-21 | 2017-04-04 | Wuhan Yzy Biopharma Co., Ltd. | Construction and application of bispecific antibody HER2xCD3 |
WO2016036678A1 (en) * | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations of bispecific antibodies |
EP3875481A1 (en) | 2014-11-14 | 2021-09-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
LT3223845T (en) | 2014-11-26 | 2021-08-25 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
EA037065B1 (en) | 2014-11-26 | 2021-02-01 | Ксенкор, Инк. | Heterodimeric antibodies that bind cd3 and cd38 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
ES2744540T3 (en) | 2014-12-05 | 2020-02-25 | Hoffmann La Roche | Anti-CD79b antibodies and usage procedures |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
CN104592393B (en) * | 2015-01-21 | 2018-09-28 | 武汉友芝友生物制药有限公司 | The structure of bispecific antibody CD19 × CD3 a kind of and application |
MX2017010795A (en) | 2015-02-24 | 2018-04-11 | Bioatla Llc | Conditionally active biological proteins. |
KR20170140180A (en) | 2015-02-24 | 2017-12-20 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
WO2016140925A1 (en) | 2015-03-02 | 2016-09-09 | Synthetic Genomics, Inc. | Regulatory elements from labyrinthulomycetes microorganisms |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
HUE049081T2 (en) | 2015-03-20 | 2020-09-28 | The United States Of America As | Neutralizing antibodies to gp120 and their use |
TWI820377B (en) | 2015-05-07 | 2023-11-01 | 美商艾吉納斯公司 | Anti-ox40 antibodies and methods of use thereof |
ES2889906T3 (en) * | 2015-05-21 | 2022-01-14 | Harpoon Therapeutics Inc | Trispecific binding proteins and medical uses |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
EP3322735A4 (en) | 2015-07-15 | 2019-03-13 | Zymeworks Inc. | Drug-conjugated bi-specific antigen-binding constructs |
TWI796283B (en) * | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
TWI717375B (en) * | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
MA44909A (en) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | THERAPEUTIC ASSOCIATION OF A CD19 INHIBITOR AND A BTK INHIBITOR |
CA2997809A1 (en) | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
EP4011911A1 (en) | 2015-11-03 | 2022-06-15 | The United States of America as represented by The Secretary Department of Health and Human Services | Neutralizing antibodies to hiv-1 gp41 and their use |
AU2016364889B2 (en) | 2015-12-02 | 2024-01-04 | Agenus Inc. | Antibodies and methods of use thereof |
KR20180085800A (en) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | CD3 and heterodimeric antibodies that bind to PSMA |
TW202302631A (en) * | 2016-03-08 | 2023-01-16 | 日商武田藥品工業股份有限公司 | Inducible binding proteins and methods of use |
US10584347B2 (en) * | 2016-03-16 | 2020-03-10 | Conagen Inc. | Production of proteins in labyrinthulomycetes |
KR102360742B1 (en) * | 2016-04-28 | 2022-02-08 | 바이오뮤넥스 파마슈티컬스 | Bispecific antibodies targeting EGFR and HER2 |
WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
CN107365387B (en) | 2016-05-12 | 2022-03-15 | 阿思科力(苏州)生物科技有限公司 | Bispecific antigen binding construct, preparation method and application thereof |
US11339225B2 (en) | 2016-05-12 | 2022-05-24 | Asclepius (Suzhou) Technology Company Group, Co., Ltd. | Bispecific antigen-binding construct and preparation method and use thereof |
AU2017285218A1 (en) | 2016-06-14 | 2018-12-06 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
CN109641049B (en) | 2016-06-21 | 2023-07-07 | 特尼奥生物股份有限公司 | CD3 binding antibodies |
EP4050032A1 (en) | 2016-06-28 | 2022-08-31 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
JP7175769B2 (en) * | 2016-06-30 | 2022-11-21 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Improved adoptive T-cell therapy |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
AU2017327723B2 (en) | 2016-09-14 | 2022-11-17 | Teneobio, Inc. | CD3 binding antibodies |
SG11201903302UA (en) | 2016-10-14 | 2019-05-30 | Xencor Inc | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
US10633454B2 (en) | 2016-11-01 | 2020-04-28 | Conagen Inc. | Expression of modified glycoproteins and glycopeptides |
CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
JP2019535262A (en) * | 2016-11-11 | 2019-12-12 | オートラス リミテッド | Chimeric antigen receptor |
IL300729A (en) | 2016-12-21 | 2023-04-01 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
CN108264559B (en) * | 2016-12-30 | 2021-08-10 | 惠和生物技术(上海)有限公司 | Tri-functional molecule combined with CD19, CD3 and T cell positive co-stimulatory molecule and application thereof |
CN106589129B (en) * | 2016-12-30 | 2021-03-05 | 上海近岸生物科技有限公司 | Tri-functional molecule combined with CD19, CD3 and CD28 and application thereof |
CN108264561B (en) * | 2016-12-30 | 2021-09-10 | 惠和生物技术(上海)有限公司 | Tri-functional molecule combining CD19, CD3 and T cell negative co-stimulatory molecule and application thereof |
SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
US11021535B2 (en) | 2017-02-10 | 2021-06-01 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
WO2018152518A1 (en) | 2017-02-20 | 2018-08-23 | Adimab, Llc | Proteins binding her2, nkg2d and cd16 |
JP7240335B2 (en) | 2017-06-20 | 2023-03-15 | テネオワン, インコーポレイテッド | Anti-BCMA heavy chain only antibody |
MA49517A (en) | 2017-06-30 | 2020-05-06 | Xencor Inc | TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND AREAS OF ANTIGEN BINDING |
EP3652206A1 (en) | 2017-07-10 | 2020-05-20 | International-Drug-Development-Biotech | Treatment of b cell malignancies using afucosylated pro-apoptotic anti-cd19 antibodies in combination with anti cd20 antibodies or chemotherapeutics |
WO2019018538A1 (en) * | 2017-07-20 | 2019-01-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Recombinant cd123-binding antibodies |
EP3664814A4 (en) | 2017-08-11 | 2021-05-05 | City of Hope | Rna aptamers against transferrin receptor (tfr) |
IL302614A (en) | 2017-09-08 | 2023-07-01 | Maverick Therapeutics Inc | Constrained conditionally activated binding proteins |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CN112272563A (en) | 2017-11-08 | 2021-01-26 | Xencor股份有限公司 | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
MA51291A (en) | 2017-12-19 | 2020-10-28 | Xencor Inc | MODIFIED IL-2 FC FUSION PROTEINS |
MX2020006715A (en) | 2017-12-27 | 2020-08-20 | Teneobio Inc | Cd3-delta/epsilon heterodimer specific antibodies. |
WO2019136029A1 (en) | 2018-01-02 | 2019-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
CN112368012A (en) | 2018-02-08 | 2021-02-12 | 蜻蜓疗法股份有限公司 | Antibody variable domains targeting NKG2D receptor |
CA3091437A1 (en) | 2018-02-21 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
JP2021520829A (en) | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | TIM-3 targeted heterodimer fusion protein containing IL-15 / IL-15RA Fc fusion protein and TIM-3 antigen binding domain |
CN112867734A (en) | 2018-04-18 | 2021-05-28 | Xencor股份有限公司 | PD-1 targeting heterodimeric fusion proteins comprising an IL-15/IL-15Ra Fc fusion protein and a PD-1 antigen binding domain and uses thereof |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
MX2021000163A (en) | 2018-07-02 | 2021-05-27 | Amgen Inc | Anti-steap1 antigen-binding protein. |
CA3115096A1 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
WO2020132214A2 (en) | 2018-12-20 | 2020-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
US11472890B2 (en) | 2019-03-01 | 2022-10-18 | Xencor, Inc. | Heterodimeric antibodies that bind ENPP3 and CD3 |
EP3934762A1 (en) | 2019-03-05 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
US20220227853A1 (en) | 2019-05-03 | 2022-07-21 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
JOP20210298A1 (en) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | Methods and compositions for preventing type 1 diabetes |
US20230085439A1 (en) | 2019-05-21 | 2023-03-16 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
JOP20210323A1 (en) | 2019-06-14 | 2023-01-30 | Teneobio Inc | Multispecific heavy chain antibodies binding to cd22 and cd3 |
CN114269783B (en) | 2019-07-02 | 2024-03-26 | 美国政府(由卫生和人类服务部的部长所代表) | Monoclonal antibody binding to EGFRVIII and application thereof |
EP3865513A1 (en) * | 2020-02-17 | 2021-08-18 | Fundación Para La Investigación Biomédica Del Hospital 12 De Octubre | Anti-cd19/anti-cd3 bispecific antibody, t cells secreting the same, method of preparation and use thereof |
EP4186564A1 (en) | 2020-04-29 | 2023-05-31 | Teneoone, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
US20230272071A1 (en) * | 2020-07-27 | 2023-08-31 | Michael S. Kuhns | Multifunctional immunoglobulin-fold polypeptides from alternative translational initiation and termination |
EP4188962A1 (en) * | 2020-07-29 | 2023-06-07 | Gritstone bio, Inc. | Engineered multi-specific antibodies and related methods of use and manufacture |
EP4200332A1 (en) | 2020-08-19 | 2023-06-28 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
JPWO2022045247A1 (en) | 2020-08-27 | 2022-03-03 | ||
WO2022109611A1 (en) | 2020-11-20 | 2022-05-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
KR20230157315A (en) | 2021-01-28 | 2023-11-16 | 리제너론 파마슈티칼스 인코포레이티드 | Compositions and methods for treating cytokine release syndrome |
US20240117019A1 (en) | 2021-02-09 | 2024-04-11 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
JP2024506315A (en) | 2021-02-09 | 2024-02-13 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Antibodies that target the coronavirus spike protein |
KR20230156079A (en) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Heterodimeric antibody binding to CD3 and CLDN6 |
JP2024509274A (en) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Heterodimeric antibody that binds to CD3 and GPC3 |
WO2023028612A2 (en) | 2021-08-27 | 2023-03-02 | Board Of Regents, The University Of Texas System | Anti-tslpr (crlf2) antibodies |
WO2023044272A1 (en) | 2021-09-17 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
WO2023154824A1 (en) | 2022-02-10 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that broadly target coronaviruses |
WO2023192881A1 (en) | 2022-03-28 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
CN116925234A (en) * | 2022-04-02 | 2023-10-24 | 合肥星眸生物科技有限公司 | AAV vector for encoding anti-VEGF-A and ANG-2 bispecific antibody |
WO2023201226A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999054440A1 (en) * | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
EP1293514A1 (en) * | 2001-09-14 | 2003-03-19 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5239062A (en) * | 1986-03-20 | 1993-08-24 | Dana-Farber Cancer Institute, Inc. | Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
CA2063035A1 (en) | 1991-03-27 | 1992-09-28 | Klaus Karjalainen | Chimaeric antibodies containing the ligand domain of cd4 |
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
WO1995011922A1 (en) | 1993-10-29 | 1995-05-04 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
WO1996036360A1 (en) | 1995-05-17 | 1996-11-21 | Regents Of The University Of Minnesota | Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies |
DE19531348A1 (en) | 1995-08-25 | 1997-02-27 | Gsf Forschungszentrum Umwelt | Antibodies with two or more specificities for the selective elimination of cells in vivo |
US7332168B2 (en) | 2000-08-22 | 2008-02-19 | Micromet Ag | Composition for the elimination of autoreactive B-cells |
-
2004
- 2004-05-26 EP EP04739378.0A patent/EP1629012B1/en active Active
- 2004-05-26 WO PCT/EP2004/005685 patent/WO2004106381A1/en active Application Filing
- 2004-05-26 CA CA2522586A patent/CA2522586C/en active Active
- 2004-05-26 US US10/554,852 patent/US7635472B2/en active Active
- 2004-05-26 AU AU2004242846A patent/AU2004242846A1/en not_active Abandoned
- 2004-05-26 RU RU2005141512/13A patent/RU2005141512A/en unknown
- 2004-05-26 JP JP2006529929A patent/JP2008501621A/en not_active Withdrawn
- 2004-05-26 CN CNB2004800145132A patent/CN100509850C/en active Active
-
2005
- 2005-10-13 ZA ZA200508280A patent/ZA200508280B/en unknown
-
2012
- 2012-10-26 JP JP2012236443A patent/JP6025502B2/en active Active
-
2015
- 2015-02-02 JP JP2015018323A patent/JP2015110628A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999054440A1 (en) * | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
EP1293514A1 (en) * | 2001-09-14 | 2003-03-19 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
Non-Patent Citations (6)
Title |
---|
DREIER TORSTEN ET AL: "T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct.", JOURNAL OF IMMUNOLOGY, vol. 170, no. 8, 15 April 2003 (2003-04-15), pages 4397 - 4402, XP002299903, ISSN: 0022-1767 * |
KIPRIYANOV S M ET AL: "Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 77, no. 5, 31 August 1998 (1998-08-31), pages 763 - 771, XP002115487, ISSN: 0020-7136 * |
KIPRIYANOV S M ET AL: "Bispecific tandem diabody for tumour therapy with improved antigen binding and pharmacokinetics", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 293, 1999, pages 41 - 56, XP004457324, ISSN: 0022-2836 * |
KIPRIYANOV S M ET AL: "Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 330, no. 1, 27 June 2003 (2003-06-27), pages 99 - 111, XP004445110, ISSN: 0022-2836 * |
LOEFFLER A ET AL: "Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.", LEUKEMIA (BASINGSTOKE), vol. 17, no. 5, May 2003 (2003-05-01), pages 900 - 909, XP002299902, ISSN: 0887-6924 * |
LOEFFLER ANJA ET AL: "A recombinant bispecific single-chain antibody, CD19 X CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes", BLOOD, vol. 95, no. 6, 15 March 2000 (2000-03-15), pages 2098 - 2103, XP002299904, ISSN: 0006-4971 * |
Cited By (231)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8101722B2 (en) | 2004-02-16 | 2012-01-24 | Micromet Ag | Less immunogenic binding molecules |
WO2005077982A1 (en) * | 2004-02-16 | 2005-08-25 | Micromet Ag | Less immunogenic binding molecules |
US10071158B2 (en) | 2005-04-26 | 2018-09-11 | Lindis Biotech Gmbh | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
US10576149B2 (en) | 2005-04-26 | 2020-03-03 | Lindis Biotech Gmbh | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
US8709421B2 (en) | 2005-04-26 | 2014-04-29 | Trion Pharma Gmbh | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
US8629257B2 (en) | 2005-06-30 | 2014-01-14 | Abbvie Inc. | IL-12/p40 binding proteins |
US11925684B2 (en) | 2005-10-11 | 2024-03-12 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
US11154617B2 (en) | 2005-12-16 | 2021-10-26 | Amgen Research (Munich) Gmbh | Means and methods for the treament of B cell non-hodgkin lymphoma and B cell leukemia |
JP2009519257A (en) * | 2005-12-16 | 2009-05-14 | ミクロメット・アクチェンゲゼルシャフト | Means and methods for treating neoplastic diseases |
JP2014028840A (en) * | 2005-12-16 | 2014-02-13 | Amgen Research (Munich) Gmbh | Means and methods for the treatment of tumorous diseases |
US8007796B2 (en) | 2005-12-16 | 2011-08-30 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
WO2007068354A1 (en) | 2005-12-16 | 2007-06-21 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
AU2013202375B2 (en) * | 2005-12-16 | 2016-10-27 | Amgen Research (Munich) Gmbh | Means and Methods for the Treatment of Tumorous Diseases |
EP2383297A1 (en) | 2006-08-14 | 2011-11-02 | Xencor Inc. | Optimized antibodies that target CD19 |
US10626182B2 (en) | 2006-08-14 | 2020-04-21 | Xencor, Inc. | Optimized antibodies that target CD19 |
US11618788B2 (en) | 2006-08-14 | 2023-04-04 | Xencor, Inc. | Optimized antibodies that target CD19 |
US8524867B2 (en) | 2006-08-14 | 2013-09-03 | Xencor, Inc. | Optimized antibodies that target CD19 |
US9803020B2 (en) | 2006-08-14 | 2017-10-31 | Xencor, Inc. | Optimized antibodies that target CD19 |
US9592293B2 (en) | 2006-09-08 | 2017-03-14 | Abbvie Inc. | Interleukin-13 binding proteins |
US11344621B2 (en) | 2006-09-08 | 2022-05-31 | Abbvie, Inc. | Interleukin-13 binding proteins |
US10086076B2 (en) | 2006-09-08 | 2018-10-02 | Abbvie Inc. | Interleukin-13 binding proteins |
US8604177B2 (en) | 2006-09-08 | 2013-12-10 | Abbvie Inc. | Interleukin-13 binding proteins |
WO2009007124A1 (en) * | 2007-07-10 | 2009-01-15 | Friedrich-Alexander-Universität | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
US10919965B2 (en) | 2008-07-18 | 2021-02-16 | Bristol-Myers Squibb Company | Compositions monovalent for CD28 binding and methods of use |
US9908937B2 (en) | 2008-07-18 | 2018-03-06 | Bristol-Myers Squibb Company | Compositions monovalent for CD28 binding and methods of use |
EP3106468A1 (en) * | 2008-10-01 | 2016-12-21 | Amgen Research (Munich) GmbH | Cross-species-specific psmaxcd3 bispecific single chain antibody |
CN102171248A (en) * | 2008-10-01 | 2011-08-31 | 米克罗麦特股份公司 | Cross-species-specific PSMAxCD3 bispecific single chain antibody |
US10047159B2 (en) | 2008-10-01 | 2018-08-14 | Amgen Research (Munich) Gmbh | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
EP3375790A1 (en) * | 2008-10-01 | 2018-09-19 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
WO2010037835A2 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
WO2010037838A2 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
WO2010037837A2 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
WO2010037838A3 (en) * | 2008-10-01 | 2010-07-08 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
CN102164961B (en) * | 2008-10-01 | 2014-04-16 | 安进研发(慕尼黑)股份有限公司 | Cross-species-specific PSCAxCD3, CD19xCD3, C-NETxCD3, endosialinxCD3, EpCAMxCD3, IGF-1RxCD3 or FAOalpha xCD3 bispecific single chain antibody |
WO2010037835A3 (en) * | 2008-10-01 | 2010-07-15 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
WO2010037837A3 (en) * | 2008-10-01 | 2010-07-22 | Micromet Ag | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
WO2010037836A3 (en) * | 2008-10-01 | 2010-07-22 | Micromet Ag | Cross-species-specific psmaxcd3 bispecific single chain antibody |
CN102164961A (en) * | 2008-10-01 | 2011-08-24 | 米克罗麦特股份公司 | Cross-species-specific PSCAxCD3, CD19xCD3, C-NETxCD3, endosialinxCD3, EpCAMxCD3, IGF-1RxCD3 or FAOalpha xCD3 bispecific single chain antibody |
EP4180458A1 (en) * | 2008-10-01 | 2023-05-17 | Amgen Research (Munich) GmbH | Cross-species-specific psma x cd3 bispecific single chain antibody |
EP2370467B1 (en) | 2008-10-01 | 2016-09-07 | Amgen Research (Munich) GmbH | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
CN102171248B (en) * | 2008-10-01 | 2015-07-15 | 安进研发(慕尼黑)股份有限公司 | Cross-species-specific PSMAxCD3 bispecific single chain antibody |
AU2009299794B2 (en) * | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
US9260522B2 (en) | 2008-10-01 | 2016-02-16 | Amgen Research (Munich) Gmbh | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
EP3330293A1 (en) | 2008-11-07 | 2018-06-06 | Amgen Research (Munich) GmbH | Treatment of pediatric acute lymphoblastic leukemia |
WO2010052013A1 (en) | 2008-11-07 | 2010-05-14 | Micromet Ag | Treatment of pediatric acute lymphoblastic leukemia |
EP2982696A2 (en) | 2008-11-07 | 2016-02-10 | Amgen Research (Munich) GmbH | Treatment of acute lymphoblastic leukemia |
EP2918604A1 (en) | 2008-11-07 | 2015-09-16 | Amgen Research (Munich) GmbH | Treatment of pediatric acute lymphoblastic leukemia |
WO2010052014A1 (en) | 2008-11-07 | 2010-05-14 | Micromet Ag | Treatment of acute lymphoblastic leukemia |
EP3594237A1 (en) | 2008-11-07 | 2020-01-15 | Amgen Research (Munich) GmbH | Treatment of pediatric acute lymphoblastic leukemia |
RU2548746C2 (en) * | 2009-10-27 | 2015-04-20 | Эмджен Рисерч (Мьюник), ГмбХ | Dose schedule for administering cd19×cd3 bispecific antibody |
WO2011051307A1 (en) | 2009-10-27 | 2011-05-05 | Micromet Ag | Dosage regimen for administering a cd19xcd3 bispecific antibody |
US10662243B2 (en) | 2009-10-27 | 2020-05-26 | Amgen Research (Munich) Gmbh | Dosage regimen for administering a CD19XCD3 bispecific antibody |
AU2010311559B2 (en) * | 2009-10-27 | 2016-07-07 | Amgen Research (Munich) Gmbh | Dosage regimen for administering a CD19xCD3 bispecific antibody |
US8840888B2 (en) | 2009-10-27 | 2014-09-23 | Micromet Ag | Dosage regimen for administering a CD19XCD3 bispecific antibody |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
CN102250245B (en) * | 2010-05-27 | 2014-05-14 | 四川大学 | Bispecific antibody capable of resisting B cell lymphoma and application thereof |
CN102250245A (en) * | 2010-05-27 | 2011-11-23 | 四川大学 | Bispecific antibody capable of resisting B cell lymphoma and application thereof |
WO2012010561A1 (en) | 2010-07-19 | 2012-01-26 | International - Drug - Development - Biotech | Anti-cd19 antibody having adcc function with improved glycosylation profile |
WO2012010562A1 (en) | 2010-07-19 | 2012-01-26 | International - Drug - Development - Biotech | Anti-cd19 antibody having adcc and cdc functions and improved glycosylation profile |
EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
US9187564B2 (en) | 2010-10-05 | 2015-11-17 | Hoffmann-La Roche Inc. | Antibodies against human TWEAK and uses thereof |
WO2012055961A1 (en) | 2010-10-27 | 2012-05-03 | Micromet Gmbh | Means and methods for treating dlbcl |
EP3412687A1 (en) | 2010-10-27 | 2018-12-12 | Amgen Research (Munich) GmbH | Methods for treating dlbcl |
EP3018145A1 (en) | 2010-10-27 | 2016-05-11 | Amgen Research (Munich) GmbH | Means and methods for treating dlbcl |
WO2012062596A1 (en) | 2010-11-10 | 2012-05-18 | Micromet Gmbh | Prevention of adverse effects caused by cd3 specific binding domains |
EP3831386A1 (en) | 2010-11-10 | 2021-06-09 | Amgen Research (Munich) GmbH | Prevention of adverse effects caused by cd3 specific binding domains |
EP3228315A1 (en) | 2010-11-10 | 2017-10-11 | Amgen Research (Munich) GmbH | Prevention of adverse effects caused by cd3 specific binding domains |
EP3974453A2 (en) | 2010-11-16 | 2022-03-30 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
WO2012066058A1 (en) | 2010-11-16 | 2012-05-24 | Boehringer Ingelheim International Gmbh | Agents and methods for treating diseases that correlate with bcma expression |
EP3974453A3 (en) * | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
US10191034B2 (en) | 2011-04-28 | 2019-01-29 | Amgen Research (Munich) Gmbh | Dosage regimen for administrating a CD19×CD3 bispecific antibody to patients at risk for potential adverse effects |
WO2012146394A1 (en) | 2011-04-28 | 2012-11-01 | Amgen Research (Munich) Gmbh | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
US11579142B2 (en) | 2011-04-28 | 2023-02-14 | Amgen Research (Munich) Gmbh | Dosage regimen for administering a CD19xCD3 bispecific antibody to patients at risk for potential adverse effects |
EP3753572A1 (en) | 2011-04-28 | 2020-12-23 | Amgen Research (Munich) GmbH | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
US11111299B2 (en) | 2011-05-21 | 2021-09-07 | Macrogenics, Inc. | CD3-binding molecules capable of binding to human and non-human CD3 |
US10150812B2 (en) | 2011-05-21 | 2018-12-11 | Macrogenics, Inc. | CD3-binding molecules capable of binding to human and non-human CD3 |
CN107722124A (en) * | 2011-05-21 | 2018-02-23 | 宏观基因有限公司 | The CD3 binding molecules that can be combined with people and inhuman CD3 |
EP3492494A1 (en) * | 2011-05-21 | 2019-06-05 | MacroGenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
US9587021B2 (en) | 2011-05-21 | 2017-03-07 | Macrogenics, Inc. | CD3-binding molecules capable of binding to human and non-human CD3 |
EP2714733A4 (en) * | 2011-05-21 | 2015-10-14 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
US9987231B2 (en) | 2011-12-28 | 2018-06-05 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
US10603283B2 (en) | 2011-12-28 | 2020-03-31 | Genus Lifesciences, Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
US10202452B2 (en) | 2012-04-20 | 2019-02-12 | Aptevo Research And Development Llc | CD3 binding polypeptides |
EP4116427A1 (en) | 2012-05-17 | 2023-01-11 | Kymab Limited | In vivo guided selection & antibodies |
US11795240B2 (en) | 2012-07-13 | 2023-10-24 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
US9765156B2 (en) | 2012-07-13 | 2017-09-19 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
WO2014011988A3 (en) * | 2012-07-13 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
US10696749B2 (en) | 2012-07-13 | 2020-06-30 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
WO2014122251A2 (en) | 2013-02-08 | 2014-08-14 | Amgen Research (Munich) Gmbh | Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains |
EP3760210A1 (en) | 2013-02-08 | 2021-01-06 | Amgen Research (Munich) GmbH | Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains |
US9688760B2 (en) | 2013-02-08 | 2017-06-27 | Amgen Research (Munich) Gmbh | Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains |
US9486475B2 (en) | 2013-02-08 | 2016-11-08 | Amgen Research (Munich) Gmbh | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
US11084876B2 (en) | 2013-02-08 | 2021-08-10 | Amgen Research (Munich) Gmbh | Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains |
JP2016526915A (en) * | 2013-08-06 | 2016-09-08 | シェンジェン インスティテュート オブ アドバーンスド テクノロジー | Mini-circle DNA recombination parent plasmid having genetically engineered antibody gene expression cassette, mini-circle DNA having the expression cassette and use [see related applications] This application is named “Gene engineered antibody gene expression” Claiming the priority of Chinese patent application 2013103399305.0 filed on Aug. 06, 2013, entitled "Minicircle DNA recombinant parent plasmid with cassette, minicircle DNA with its expression cassette and use" The entire contents are hereby incorporated by reference. |
EP3647324A1 (en) | 2013-12-17 | 2020-05-06 | F. Hoffmann-La Roche AG | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
EP3680254A1 (en) | 2013-12-17 | 2020-07-15 | F. Hoffmann-La Roche AG | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
WO2015095410A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
WO2015095418A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
EP3531133A1 (en) | 2014-05-30 | 2019-08-28 | Amgen Research (Munich) GmbH | Risk-stratification of b-precursor acute lymphoblastic leukemia patients |
EP4303585A2 (en) | 2014-05-30 | 2024-01-10 | Amgen Research (Munich) GmbH | Risk-stratification of b-precursor acute lymphoblastic leukemia patients |
US11079381B2 (en) | 2014-05-30 | 2021-08-03 | Amgen Research (Munich) Gmbh | Risk-stratification of B-precursor acute lymphoblastic leukemia patients |
WO2015181683A1 (en) | 2014-05-30 | 2015-12-03 | Amgen Research (Munich) Gmbh | Risk-stratification of b-precursor acute lymphoblastic leukemia patients |
US11084880B2 (en) | 2014-07-21 | 2021-08-10 | Novartis Ag | Anti-BCMA chimeric antigen receptor |
US10174095B2 (en) | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
US10568947B2 (en) | 2014-07-21 | 2020-02-25 | Novartis Ag | Treatment of cancer using a CLL-1 chimeric antigen receptor |
US10066002B2 (en) | 2014-11-05 | 2018-09-04 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
US11299539B2 (en) | 2014-11-05 | 2022-04-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
US11091530B2 (en) | 2014-11-05 | 2021-08-17 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
WO2016073794A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
EP3753948A1 (en) | 2014-11-05 | 2020-12-23 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
WO2016073791A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
US10112994B2 (en) | 2014-11-05 | 2018-10-30 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
WO2016087245A1 (en) | 2014-12-01 | 2016-06-09 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific t cell-activation |
US10988533B2 (en) | 2015-02-05 | 2021-04-27 | Unm Rainforest Innovations | Anti-pre-BCR antagonists and methods |
WO2016127043A1 (en) * | 2015-02-05 | 2016-08-11 | Stc.Unm | Anti-pre-bcr antagonists and methods |
EP3064507A1 (en) | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
WO2016142314A1 (en) | 2015-03-06 | 2016-09-15 | Deutsches Krebsforschungszentrum | FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOF |
US11254987B2 (en) | 2015-05-29 | 2022-02-22 | Genentech, Inc. | PD-L1 promoter methylation in cancer |
EP3763827A1 (en) | 2015-05-29 | 2021-01-13 | F. Hoffmann-La Roche AG | Pd-l1 promoter methylation in cancer |
WO2016196381A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Pd-l1 promoter methylation in cancer |
WO2016205320A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
US11713358B2 (en) | 2015-08-28 | 2023-08-01 | Amunix Pharmaceuticals, Inc. | Chimeric polypeptide assembly and methods of making and using the same |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
US11286300B2 (en) | 2015-10-01 | 2022-03-29 | Hoffmann-La Roche Inc. | Humanized anti-human CD19 antibodies and methods of use |
WO2017055314A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-cd19xcd3 t cell activating antigen binding molecules |
EP3913000A1 (en) | 2015-10-02 | 2021-11-24 | F. Hoffmann-La Roche AG | Bispecific anti-cd19xcd3 t cell activating antigen binding molecules |
WO2017096368A1 (en) * | 2015-12-04 | 2017-06-08 | Macrogenics, Inc. | Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof |
EP4026848A1 (en) | 2015-12-09 | 2022-07-13 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing the cytokine release syndrome |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
US11840571B2 (en) | 2015-12-14 | 2023-12-12 | Macrogenics, Inc. | Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4 |
US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
EP3862365A1 (en) | 2016-01-08 | 2021-08-11 | F. Hoffmann-La Roche AG | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
WO2017129585A1 (en) * | 2016-01-25 | 2017-08-03 | Amgen Research (Munich) Gmbh | Pharmaceutical composition comprising bispecific antibody constructs |
US11419933B2 (en) | 2016-01-25 | 2022-08-23 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
WO2018029124A1 (en) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
WO2018114754A1 (en) | 2016-12-19 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
WO2018114748A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists |
US11535666B2 (en) * | 2016-12-30 | 2022-12-27 | Cytocares (Shanghai) Inc. | Trifunctional molecule and application thereof |
US11685790B2 (en) | 2017-04-03 | 2023-06-27 | Hoffmann-La Roche Inc. | Antibodies binding to STEAP-1 |
WO2018184966A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Antibodies binding to steap-1 |
US11180571B2 (en) | 2017-04-03 | 2021-11-23 | Hoffmann-La Roche Inc. | Antibodies binding to STEAP-1 |
WO2018220099A1 (en) | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
US11597759B2 (en) | 2017-06-21 | 2023-03-07 | Gilead Sciences, Inc. | Multispecific antibodies that target HIV GP120 and CD3 |
US11827713B2 (en) | 2017-06-27 | 2023-11-28 | Nanjing Legend Biotech Co., Ltd. | Chimeric antibody immune effector cell engagers and methods of use thereof |
US11440972B2 (en) | 2017-08-01 | 2022-09-13 | Ab Studio Inc. | Bispecific antibodies and uses thereof |
US11566083B2 (en) | 2017-08-01 | 2023-01-31 | Ab Studio Inc. | Bispecific antibodies and uses thereof |
US11541103B2 (en) | 2017-08-03 | 2023-01-03 | Amgen Inc. | Interleukin-21 mutein/ anti-PD-1 antibody conjugates |
US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
WO2019075366A1 (en) | 2017-10-13 | 2019-04-18 | Merck Sharp & Dohme Corp. | Compositions and methods for treating diffuse large b cell lymphoma |
WO2019086497A2 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Combination therapy with targeted ox40 agonists |
US11795226B2 (en) | 2017-12-12 | 2023-10-24 | Macrogenics, Inc. | Bispecific CD16-binding molecules and their use in the treatment of disease |
US11192957B2 (en) | 2017-12-21 | 2021-12-07 | Hoffmann-La Roche Inc. | Antibodies binding to HLA-A2/WT1 |
WO2019122052A2 (en) | 2017-12-21 | 2019-06-27 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a2/wt1 |
WO2019126634A2 (en) | 2017-12-22 | 2019-06-27 | Genentech, Inc. | Targeted integration of nucleic acids |
WO2019140196A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Anti-pd-1 antibodies and methods of treatment |
US11518808B2 (en) | 2018-01-12 | 2022-12-06 | Amgen Inc. | Anti-PD-1 antibodies and methods of treatment |
WO2019149716A1 (en) | 2018-01-31 | 2019-08-08 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
WO2019149715A1 (en) | 2018-01-31 | 2019-08-08 | F. Hoffmann-La Roche Ag | Stabilized immunoglobulin domains |
WO2019154890A1 (en) | 2018-02-09 | 2019-08-15 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
US11685781B2 (en) | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
WO2019175071A1 (en) | 2018-03-13 | 2019-09-19 | F. Hoffmann-La Roche Ag | Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies |
WO2019175125A1 (en) | 2018-03-13 | 2019-09-19 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
WO2019191552A1 (en) | 2018-03-29 | 2019-10-03 | Genentech, Inc. | Modulating lactogenic activity in mammalian cells |
WO2019202041A1 (en) | 2018-04-18 | 2019-10-24 | F. Hoffmann-La Roche Ag | Multispecific antibodies and use thereof |
US11952428B2 (en) | 2018-06-13 | 2024-04-09 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
US11939389B2 (en) | 2018-06-13 | 2024-03-26 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
WO2020058297A1 (en) | 2018-09-18 | 2020-03-26 | F. Hoffmann-La Roche Ag | Use of a cathepsin s inhibitor against the formation of anti-drug antibodies |
EP4249917A2 (en) | 2018-09-21 | 2023-09-27 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
WO2020061349A1 (en) | 2018-09-21 | 2020-03-26 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
WO2020096959A1 (en) | 2018-11-05 | 2020-05-14 | Genentech, Inc. | Methods of producing two chain proteins in prokaryotic host cells |
WO2020127619A1 (en) | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
WO2020132165A1 (en) | 2018-12-21 | 2020-06-25 | Genentech, Inc. | Targeted integration of nucleic acids |
WO2020141145A1 (en) | 2018-12-30 | 2020-07-09 | F. Hoffmann-La Roche Ag | Anti-rabbit cd19 antibodies and methods of use |
US10988517B2 (en) * | 2019-01-07 | 2021-04-27 | Shattuck Labs, Inc. | Heterodimeric proteins for modulating gamma delta T cells |
WO2020154410A1 (en) | 2019-01-23 | 2020-07-30 | Genentech, Inc. | Methods of producing multimeric proteins in eukaryotic host cells |
WO2020221792A1 (en) | 2019-04-30 | 2020-11-05 | Amgen Research (Munich) Gmbh | Means and methods of treating burkitt lymphoma or leukemia |
WO2021018925A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
WO2021018859A2 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
CN110577603A (en) * | 2019-08-15 | 2019-12-17 | 北京东方百泰生物科技有限公司 | anti-CD 3 and anti-CD 19 bispecific antibody |
WO2021041300A3 (en) * | 2019-08-23 | 2021-04-01 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
WO2021055577A2 (en) | 2019-09-18 | 2021-03-25 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
WO2021122875A1 (en) | 2019-12-18 | 2021-06-24 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a2/mage-a4 |
WO2021133723A2 (en) | 2019-12-23 | 2021-07-01 | Genentech, Inc. | Apolipoprotein l1-specific antibodies and methods of use |
WO2021146336A1 (en) | 2020-01-13 | 2021-07-22 | Aptevo Research And Development Llc | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
WO2021146328A1 (en) | 2020-01-13 | 2021-07-22 | Aptevo Research And Development Llc | Formulations for protein therapeutics |
WO2021183207A1 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER |
WO2021195464A2 (en) | 2020-03-26 | 2021-09-30 | Genentech, Inc. | Modified mammalian cells |
WO2021214277A1 (en) | 2020-04-24 | 2021-10-28 | F. Hoffmann-La Roche Ag | Enzyme and pathway modulation with sulfhydryl compounds and their derivatives |
WO2021249990A2 (en) | 2020-06-08 | 2021-12-16 | Hoffmann-La Roche Inc. | Anti-hbv antibodies and methods of use |
WO2021257503A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
US11780920B2 (en) | 2020-06-19 | 2023-10-10 | Hoffmann-La Roche Inc. | Antibodies binding to CD3 and CD19 |
WO2021255155A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cd19 |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
WO2021255143A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and folr1 |
WO2021255142A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
WO2021262798A1 (en) | 2020-06-24 | 2021-12-30 | Genentech, Inc. | Targeted integration of nucleic acids |
WO2021262783A1 (en) | 2020-06-24 | 2021-12-30 | Genentech, Inc. | Apoptosis resistant cell lines |
WO2022016037A1 (en) | 2020-07-17 | 2022-01-20 | Genentech, Inc. | Anti-notch2 antibodies and methods of use |
WO2022018262A1 (en) * | 2020-07-24 | 2022-01-27 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
WO2022047222A2 (en) | 2020-08-28 | 2022-03-03 | Genentech, Inc. | Crispr/cas9 multiplex knockout of host cell proteins |
WO2022129120A1 (en) | 2020-12-17 | 2022-06-23 | F. Hoffmann-La Roche Ag | Anti-hla-g antibodies and use thereof |
WO2022169825A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
WO2022169872A1 (en) | 2021-02-03 | 2022-08-11 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
WO2022192647A1 (en) | 2021-03-12 | 2022-09-15 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
WO2022225880A1 (en) | 2021-04-19 | 2022-10-27 | Genentech, Inc. | Modified mammalian cells |
WO2022226317A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
WO2022228706A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
WO2022246259A1 (en) | 2021-05-21 | 2022-11-24 | Genentech, Inc. | Modified cells for the production of a recombinant product of interest |
WO2022246244A1 (en) | 2021-05-21 | 2022-11-24 | Aptevo Research And Development Llc | Dosing regimens for protein therapeutics |
WO2023280227A2 (en) | 2021-07-06 | 2023-01-12 | Profoundbio Us Co. | Linkers, drug linkers and conjugates thereof and methods of using the same |
WO2023287663A1 (en) | 2021-07-13 | 2023-01-19 | Genentech, Inc. | Multi-variate model for predicting cytokine release syndrome |
WO2023001884A1 (en) | 2021-07-22 | 2023-01-26 | F. Hoffmann-La Roche Ag | Heterodimeric fc domain antibodies |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
WO2023062188A1 (en) | 2021-10-15 | 2023-04-20 | Amgen Research (Munich) Gmbh | Subcutaneous administration of cd19-binding t cell engaging antibodies |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
WO2023104938A1 (en) | 2021-12-10 | 2023-06-15 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and plap |
WO2023141445A1 (en) | 2022-01-19 | 2023-07-27 | Genentech, Inc. | Anti-notch2 antibodies and conjugates and methods of use |
WO2023180353A1 (en) | 2022-03-23 | 2023-09-28 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
EP1629012B1 (en) | 2018-11-28 |
US7635472B2 (en) | 2009-12-22 |
CA2522586C (en) | 2017-02-21 |
CN1795208A (en) | 2006-06-28 |
CA2522586A1 (en) | 2004-12-09 |
EP1629012A1 (en) | 2006-03-01 |
JP2015110628A (en) | 2015-06-18 |
AU2004242846A1 (en) | 2004-12-09 |
JP2013063981A (en) | 2013-04-11 |
US20070123479A1 (en) | 2007-05-31 |
RU2005141512A (en) | 2007-07-20 |
ZA200508280B (en) | 2007-04-25 |
JP2008501621A (en) | 2008-01-24 |
CN100509850C (en) | 2009-07-08 |
JP6025502B2 (en) | 2016-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1629012B1 (en) | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders | |
AU2004242847B2 (en) | Pharmaceutical composition comprising a bispecific antibody for EpCAM | |
EP1716178B1 (en) | Less immunogenic binding molecules | |
JP2023053239A (en) | Long life polypeptide binding molecules | |
JP2015504306A (en) | Binding molecules for BCMA and CD3 | |
AU2004283850A1 (en) | Multispecific deimmunized CD3-binders | |
ZA200508279B (en) | Pharmaceutical composition comprising a bispecific antibody for epcam |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005/08280 Country of ref document: ZA Ref document number: 200508280 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2522586 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004242846 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2918/CHENP/2005 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2004242846 Country of ref document: AU Date of ref document: 20040526 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004242846 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006529929 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004739378 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048145132 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005141512 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004739378 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007123479 Country of ref document: US Ref document number: 10554852 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10554852 Country of ref document: US |